Shlee的个人主页 - 老虎社区

Shlee

Shlee

暂无个人介绍

IP属地：未知

16关注

3粉丝

0主题

0勋章

2021-12-27

Nice

EV stocks mixed in morning trading

2021-12-23

Nice

Tesla Q4 Sales Expected To Jump 43% On Robust December Deliveries: TrueCar

2021-12-17

Nice

Nio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China

2021-12-16

Nice

U.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%

2021-12-14

Nice

抱歉，原内容已删除

2021-12-10

Beyond meat

3 High-Growth Stocks That Are Screaming Buys in December

2021-11-23

Nice

Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development

2021-11-19

Nice

Pfizer and BioNTech SE stocks climbed about 2% in premarket trading

2021-11-16

[OMG]

Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks

2021-10-29

Yes!

2 Unstoppable Stocks That Could Turn $50,000 Into $250,000 by 2030

2021-10-12

Nice

开盘：美股齐涨，中概教育股迎利好普涨

2021-10-08

Nice

抱歉，原内容已删除

2021-10-07

Nice

Nio gains after Goldman Sachs points to 60% upside potential

2021-09-30

Nice

抱歉，原内容已删除

2021-09-28

Nice

Sonoma Pharmaceuticals shares surged 45% in premarket trading

2021-09-27

Nice

China's Xiaomi invests $2B in auto-chip company Black Sesame

2021-07-30

好的开始是成功的一半

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3573647345754035,"uuid":"3573647345754035","gmtCreate":1610556776007,"gmtModify":1706620610298,"name":"Shlee","pinyin":"shlee","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":16,"tweetSize":66,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.52%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696318694,"gmtCreate":1640617094472,"gmtModify":1640617232336,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696318694","repostId":"1139095230","repostType":4,"repost":{"id":"1139095230","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640615948,"share":"https://www.laohu8.com/m/news/1139095230?lang=&edition=full","pubTime":"2021-12-27 22:39","market":"us","language":"en","title":"EV stocks mixed in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1139095230","media":"Tiger Newspress","summary":"EV stocks mixed in morning trading.Tesla,Nikola,NIO,Xpeng Motors and Li Auto climbed between 1% and ","content":"<p>EV stocks mixed in morning trading.Tesla,Nikola,NIO,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 3%.While&nbsp;Lucid&nbsp;fell&nbsp;more&nbsp;than&nbsp;4%.</p>\n<p><img src=\"https://static.tigerbbs.com/0c26aaadf8023ee7e2e15e128470dc48\" tg-width=\"417\" tg-height=\"660\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks mixed in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks mixed in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-27 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks mixed in morning trading.Tesla,Nikola,NIO,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 3%.While&nbsp;Lucid&nbsp;fell&nbsp;more&nbsp;than&nbsp;4%.</p>\n<p><img src=\"https://static.tigerbbs.com/0c26aaadf8023ee7e2e15e128470dc48\" tg-width=\"417\" tg-height=\"660\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","GOEV":"Canoo Inc.","LI":"理想汽车","FSR":"菲斯克","LCID":"Lucid Group Inc","RIVN":"Rivian Automotive, Inc.","NIO":"蔚来","XPEV":"小鹏汽车","NKLA":"Nikola Corporation"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139095230","content_text":"EV stocks mixed in morning trading.Tesla,Nikola,NIO,Xpeng Motors and Li Auto climbed between 1% and 3%.While Lucid fell more than 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698075573,"gmtCreate":1640270565309,"gmtModify":1640270565416,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698075573","repostId":"1140408431","repostType":4,"repost":{"id":"1140408431","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640258815,"share":"https://www.laohu8.com/m/news/1140408431?lang=&edition=full","pubTime":"2021-12-23 19:26","market":"us","language":"en","title":"Tesla Q4 Sales Expected To Jump 43% On Robust December Deliveries: TrueCar","url":"https://stock-news.laohu8.com/highlight/detail?id=1140408431","media":"Benzinga","summary":"Tesla Inc’s fourth-quarter sales in the U.S. are expected to jump 42.8% to 97,417 electric vehicles ","content":"<p><b>Tesla Inc’s</b>&nbsp;fourth-quarter sales in the U.S. are expected to jump 42.8% to 97,417 electric vehicles from a year ago and 28.8% over the previous quarter, the latest automotive industry forecast from&nbsp;<b>TrueCar</b>&nbsp;reflected on Wednesday.</p>\n<p><b>What Happened:</b>The&nbsp;<b>Elon Musk</b>-led company is expected to deliver 36,300 electric vehicles in the U.S. in December, a jump of 34.7% over last year and about 7% over November, according to TrueCar.</p>\n<p>Tesla sold 33,980 electric vehicles in November, the report noted.</p>\n<p>Musk on Wednesday said Tesla is working hard to meet the year-end delivery targets as the electric vehicle maker company’s stock rejoined the $1-trillion-market-cap club.</p>\n<p>TrueCar also forecast total new vehicle sales will reach 1,144,108 units in December, down 27% from a year ago. The research agency estimated December’s seasonally adjusted annualized rate (SAAR) for total light-vehicle sales to be 11.9 million units, down 27% from a year ago.</p>\n<p><b>How Will Legacy Players Fare?:</b>Both&nbsp;<b>General Motors Co</b>&nbsp;and&nbsp;<b>Ford Motor Co</b>&nbsp;are expected to report year-on-year declines in December sales due to the low base from a year ago when volumes were hit due to the pandemic and dealers were struggling with inventories.</p>\n<p>The sales numbers are expected to rise over November for both GM and Ford.</p>\n<p>GM’s December sales are expected to reach 168,640 vehicles, a decline of 42.9% on a year-on-year basis, and a rise of 21% over November.</p>\n<p>Ford is expected to report a decline of 20% to 166,547 vehicles in December, compared to a year ago, and a rise of 5.8% over last month.</p>\n<p>On a quarterly basis, Ford is expected to sell a total of 498,428 vehicles, a drop of 7.5% on a year-on-year basis but a rise of 25.3% over the third quarter.</p>\n<p>GM is expected to report total sales of 441,426 vehicles in the fourth quarter, implying declines of 42.5% year-on-year and down 0.4% quarter-on-quarter, the report noted.</p>\n<p>Historically, December has been a busy month for automakers as they rush to close the calendar year-end targets. This year, automakers around the world have been battling chip shortages to ensure a steady and timely supply to dealerships and customers. Legacy player Ford has earlier said it plans to&nbsp;keep inventories historically low.</p>\n<p>The report projected incentive spending in December to be down 55% from last year and 51% for the fourth quarter.</p>\n<p><b>Price Action:</b>&nbsp;Tesla shares closed 7.49% higher at $1,008.87 a share on Wednesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Q4 Sales Expected To Jump 43% On Robust December Deliveries: TrueCar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Q4 Sales Expected To Jump 43% On Robust December Deliveries: TrueCar\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-23 19:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tesla Inc’s</b>&nbsp;fourth-quarter sales in the U.S. are expected to jump 42.8% to 97,417 electric vehicles from a year ago and 28.8% over the previous quarter, the latest automotive industry forecast from&nbsp;<b>TrueCar</b>&nbsp;reflected on Wednesday.</p>\n<p><b>What Happened:</b>The&nbsp;<b>Elon Musk</b>-led company is expected to deliver 36,300 electric vehicles in the U.S. in December, a jump of 34.7% over last year and about 7% over November, according to TrueCar.</p>\n<p>Tesla sold 33,980 electric vehicles in November, the report noted.</p>\n<p>Musk on Wednesday said Tesla is working hard to meet the year-end delivery targets as the electric vehicle maker company’s stock rejoined the $1-trillion-market-cap club.</p>\n<p>TrueCar also forecast total new vehicle sales will reach 1,144,108 units in December, down 27% from a year ago. The research agency estimated December’s seasonally adjusted annualized rate (SAAR) for total light-vehicle sales to be 11.9 million units, down 27% from a year ago.</p>\n<p><b>How Will Legacy Players Fare?:</b>Both&nbsp;<b>General Motors Co</b>&nbsp;and&nbsp;<b>Ford Motor Co</b>&nbsp;are expected to report year-on-year declines in December sales due to the low base from a year ago when volumes were hit due to the pandemic and dealers were struggling with inventories.</p>\n<p>The sales numbers are expected to rise over November for both GM and Ford.</p>\n<p>GM’s December sales are expected to reach 168,640 vehicles, a decline of 42.9% on a year-on-year basis, and a rise of 21% over November.</p>\n<p>Ford is expected to report a decline of 20% to 166,547 vehicles in December, compared to a year ago, and a rise of 5.8% over last month.</p>\n<p>On a quarterly basis, Ford is expected to sell a total of 498,428 vehicles, a drop of 7.5% on a year-on-year basis but a rise of 25.3% over the third quarter.</p>\n<p>GM is expected to report total sales of 441,426 vehicles in the fourth quarter, implying declines of 42.5% year-on-year and down 0.4% quarter-on-quarter, the report noted.</p>\n<p>Historically, December has been a busy month for automakers as they rush to close the calendar year-end targets. This year, automakers around the world have been battling chip shortages to ensure a steady and timely supply to dealerships and customers. Legacy player Ford has earlier said it plans to&nbsp;keep inventories historically low.</p>\n<p>The report projected incentive spending in December to be down 55% from last year and 51% for the fourth quarter.</p>\n<p><b>Price Action:</b>&nbsp;Tesla shares closed 7.49% higher at $1,008.87 a share on Wednesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140408431","content_text":"Tesla Inc’s fourth-quarter sales in the U.S. are expected to jump 42.8% to 97,417 electric vehicles from a year ago and 28.8% over the previous quarter, the latest automotive industry forecast from TrueCar reflected on Wednesday.\nWhat Happened:The Elon Musk-led company is expected to deliver 36,300 electric vehicles in the U.S. in December, a jump of 34.7% over last year and about 7% over November, according to TrueCar.\nTesla sold 33,980 electric vehicles in November, the report noted.\nMusk on Wednesday said Tesla is working hard to meet the year-end delivery targets as the electric vehicle maker company’s stock rejoined the $1-trillion-market-cap club.\nTrueCar also forecast total new vehicle sales will reach 1,144,108 units in December, down 27% from a year ago. The research agency estimated December’s seasonally adjusted annualized rate (SAAR) for total light-vehicle sales to be 11.9 million units, down 27% from a year ago.\nHow Will Legacy Players Fare?:Both General Motors Co and Ford Motor Co are expected to report year-on-year declines in December sales due to the low base from a year ago when volumes were hit due to the pandemic and dealers were struggling with inventories.\nThe sales numbers are expected to rise over November for both GM and Ford.\nGM’s December sales are expected to reach 168,640 vehicles, a decline of 42.9% on a year-on-year basis, and a rise of 21% over November.\nFord is expected to report a decline of 20% to 166,547 vehicles in December, compared to a year ago, and a rise of 5.8% over last month.\nOn a quarterly basis, Ford is expected to sell a total of 498,428 vehicles, a drop of 7.5% on a year-on-year basis but a rise of 25.3% over the third quarter.\nGM is expected to report total sales of 441,426 vehicles in the fourth quarter, implying declines of 42.5% year-on-year and down 0.4% quarter-on-quarter, the report noted.\nHistorically, December has been a busy month for automakers as they rush to close the calendar year-end targets. This year, automakers around the world have been battling chip shortages to ensure a steady and timely supply to dealerships and customers. Legacy player Ford has earlier said it plans to keep inventories historically low.\nThe report projected incentive spending in December to be down 55% from last year and 51% for the fourth quarter.\nPrice Action: Tesla shares closed 7.49% higher at $1,008.87 a share on Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699118924,"gmtCreate":1639755143620,"gmtModify":1639755143863,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699118924","repostId":"2192462941","repostType":2,"repost":{"id":"2192462941","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1639724284,"share":"https://www.laohu8.com/m/news/2192462941?lang=&edition=full","pubTime":"2021-12-17 14:58","market":"us","language":"en","title":"Nio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2192462941","media":"Investors","summary":"A smaller electric sedan could be Tesla rival's most affordable and 'highest volume' electric vehicle yet.","content":"<p><b>Nio</b> is poised to unleash its newest electric vehicle — one that could threaten the <b>Tesla</b> Model 3 in China, while kick-starting Nio stock back to life.</p>\n<p>Ahead of the fifth annual Nio Day on Dec. 18, the Chinese EV startup teased a new model reveal at the event.</p>\n<p>Like many others, Deutsche Bank analyst Edison Yu expects that model to be the ET5, the rumored smaller version of Nio's flagship ET7 electric sedan, which was officially revealed in January.</p>\n<p>In a note Wednesday, Yu predicted that the ET5 will be Nio's most affordable and \"highest volume\" electric vehicle yet. By 2023, he expects the ET5 to outsell its larger counterpart, estimating 65,000 deliveries that year vs. 60,000 for the ET7.</p>\n<p>That's in part because Yu believes it will start in the low 300,000 RMB ($46,000) range. By comparison, Nio's existing lineup of three premium electric SUVs, as well as the upcoming ET7 sedan, are priced in the 350,000-500,000 RMB (about $55,000 to $78,500) range.</p>\n<p>In his note, Yu sees the ET5 taking on the Tesla Model 3 in China, as well as the BMW 3 series and Audi A4. The made-in-Shanghai Model 3 starts at $40,100, after discounts.</p>\n<p>Nio plans three new EVs in 2022, including the ET7 sedan. The company, which hasn't debuted a new product in well over a year, is in need of a product refresh, analysts say. Meanwhile, the ET7 is seen challenging Tesla's Model S in China.</p>\n<h2>Nio Stock, EV Stocks</h2>\n<p>Shares of Nio fell 2.3% to 30.07 on the stock market Thursday, further undercutting May's lows. The relative strength line for once-red-hot Nio stock shows severe lag. Among other EV stocks, Tesla dropped 5%. Among startup peers, <b>Xpeng</b> fell 2.1% and <b>Li Auto</b> slumped 1.5%.</p>\n<p>For Nio, the ET5 could open up the low end of the premium Chinese car market. As for the flagship, highly autonomous ET7, Yu believes it's ready to launch after a well-received reveal in January, starting around 440,000 RMB.</p>\n<p>\"We expect further details on the ET7 ahead of Q1 2022 customer deliveries\" at Nio Day, Yu wrote in his Wednesday note.</p>\n<p>At Nio Day 2021, Yu also expects more details on hybrid solid-state batteries and next-gen autonomous driving systems. He's also looking for more color on the Chinese EV startup's expansion in Europe.</p>\n<p>In September, China's Nio entered the international market with the launch of its ES8 SUV in Norway. The ET7 sedan will follow in Germany in 2022. Tesla leads the European market for electric cars.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day Could Jolt Nio Stock To Life While Threatening Tesla's Model 3 In China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-12-17 14:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Nio</b> is poised to unleash its newest electric vehicle — one that could threaten the <b>Tesla</b> Model 3 in China, while kick-starting Nio stock back to life.</p>\n<p>Ahead of the fifth annual Nio Day on Dec. 18, the Chinese EV startup teased a new model reveal at the event.</p>\n<p>Like many others, Deutsche Bank analyst Edison Yu expects that model to be the ET5, the rumored smaller version of Nio's flagship ET7 electric sedan, which was officially revealed in January.</p>\n<p>In a note Wednesday, Yu predicted that the ET5 will be Nio's most affordable and \"highest volume\" electric vehicle yet. By 2023, he expects the ET5 to outsell its larger counterpart, estimating 65,000 deliveries that year vs. 60,000 for the ET7.</p>\n<p>That's in part because Yu believes it will start in the low 300,000 RMB ($46,000) range. By comparison, Nio's existing lineup of three premium electric SUVs, as well as the upcoming ET7 sedan, are priced in the 350,000-500,000 RMB (about $55,000 to $78,500) range.</p>\n<p>In his note, Yu sees the ET5 taking on the Tesla Model 3 in China, as well as the BMW 3 series and Audi A4. The made-in-Shanghai Model 3 starts at $40,100, after discounts.</p>\n<p>Nio plans three new EVs in 2022, including the ET7 sedan. The company, which hasn't debuted a new product in well over a year, is in need of a product refresh, analysts say. Meanwhile, the ET7 is seen challenging Tesla's Model S in China.</p>\n<h2>Nio Stock, EV Stocks</h2>\n<p>Shares of Nio fell 2.3% to 30.07 on the stock market Thursday, further undercutting May's lows. The relative strength line for once-red-hot Nio stock shows severe lag. Among other EV stocks, Tesla dropped 5%. Among startup peers, <b>Xpeng</b> fell 2.1% and <b>Li Auto</b> slumped 1.5%.</p>\n<p>For Nio, the ET5 could open up the low end of the premium Chinese car market. As for the flagship, highly autonomous ET7, Yu believes it's ready to launch after a well-received reveal in January, starting around 440,000 RMB.</p>\n<p>\"We expect further details on the ET7 ahead of Q1 2022 customer deliveries\" at Nio Day, Yu wrote in his Wednesday note.</p>\n<p>At Nio Day 2021, Yu also expects more details on hybrid solid-state batteries and next-gen autonomous driving systems. He's also looking for more color on the Chinese EV startup's expansion in Europe.</p>\n<p>In September, China's Nio entered the international market with the launch of its ES8 SUV in Norway. The ET7 sedan will follow in Germany in 2022. Tesla leads the European market for electric cars.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","BK4124":"机动车零配件与设备"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192462941","content_text":"Nio is poised to unleash its newest electric vehicle — one that could threaten the Tesla Model 3 in China, while kick-starting Nio stock back to life.\nAhead of the fifth annual Nio Day on Dec. 18, the Chinese EV startup teased a new model reveal at the event.\nLike many others, Deutsche Bank analyst Edison Yu expects that model to be the ET5, the rumored smaller version of Nio's flagship ET7 electric sedan, which was officially revealed in January.\nIn a note Wednesday, Yu predicted that the ET5 will be Nio's most affordable and \"highest volume\" electric vehicle yet. By 2023, he expects the ET5 to outsell its larger counterpart, estimating 65,000 deliveries that year vs. 60,000 for the ET7.\nThat's in part because Yu believes it will start in the low 300,000 RMB ($46,000) range. By comparison, Nio's existing lineup of three premium electric SUVs, as well as the upcoming ET7 sedan, are priced in the 350,000-500,000 RMB (about $55,000 to $78,500) range.\nIn his note, Yu sees the ET5 taking on the Tesla Model 3 in China, as well as the BMW 3 series and Audi A4. The made-in-Shanghai Model 3 starts at $40,100, after discounts.\nNio plans three new EVs in 2022, including the ET7 sedan. The company, which hasn't debuted a new product in well over a year, is in need of a product refresh, analysts say. Meanwhile, the ET7 is seen challenging Tesla's Model S in China.\nNio Stock, EV Stocks\nShares of Nio fell 2.3% to 30.07 on the stock market Thursday, further undercutting May's lows. The relative strength line for once-red-hot Nio stock shows severe lag. Among other EV stocks, Tesla dropped 5%. Among startup peers, Xpeng fell 2.1% and Li Auto slumped 1.5%.\nFor Nio, the ET5 could open up the low end of the premium Chinese car market. As for the flagship, highly autonomous ET7, Yu believes it's ready to launch after a well-received reveal in January, starting around 440,000 RMB.\n\"We expect further details on the ET7 ahead of Q1 2022 customer deliveries\" at Nio Day, Yu wrote in his Wednesday note.\nAt Nio Day 2021, Yu also expects more details on hybrid solid-state batteries and next-gen autonomous driving systems. He's also looking for more color on the Chinese EV startup's expansion in Europe.\nIn September, China's Nio entered the international market with the launch of its ES8 SUV in Norway. The ET7 sedan will follow in Germany in 2022. Tesla leads the European market for electric cars.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690648910,"gmtCreate":1639666223435,"gmtModify":1639666223552,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690648910","repostId":"1103611253","repostType":4,"repost":{"id":"1103611253","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639665157,"share":"https://www.laohu8.com/m/news/1103611253?lang=&edition=full","pubTime":"2021-12-16 22:32","market":"us","language":"en","title":"U.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103611253","media":"Tiger Newspress","summary":"U.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%","content":"<p>U.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%,Dow climbs 0.5%; S&amp;P 500 advances 0.4%,S&amp;P 500 trades in record-close territory early Thursday.</p>\n<p>Shares of companies that&nbsp;have done well in previous rate-hiking cycles&nbsp;led premarket gainers. Materials stocks FMC Corp. and Freeport-McMoRan both rose more than 3% ahead of the opening bell. Bank stocks also rose across the board, with&nbsp;JPMorgan Chase,Citigroup&nbsp;and&nbsp;Bank of America&nbsp;all up about 0.6%.</p>\n<p>In transportation news,Delta Air Lines&nbsp;reported that it now expects to see a&nbsp;profit of $200 million in the fourth quarter, after previously projecting a loss. Shares rose 2.2% on the news.</p>\n<p>In other central banking news, the Bank of England announced it is hiking its key policy rate by 15 basis points to 0.25%. Markets were awaiting a separate policy decision from the European Central Bank. There also is more economic news on tap, with weekly jobless claims and housing starts out at 8:30 a.m. ET.</p>\n<p>Following the Fed news, traders accelerated their own expectations for interest rate increases. Fed funds futures trading now points to a 63% chance of the first quarter-percentage-point increase coming in May 2022, with chances also rising to about 44% that the central bank could make its first move as soon as March, according to the CME FedWatch Tool.</p>\n<p>Stocks traded in negative territory throughout the regular session Wednesday and turned higher ahead of Fed Chairman Jerome Powell’s press conference in the afternoon at the conclusion of the two-day Federal Open Market Committee meeting. The Dow added 383 points, or 1.08%. The S&amp;P 500 rose 1.63% and the tech-heavy Nasdaq Composite jumped 2.15%.</p>\n<p>“The fact that the FOMC acknowledged new COVID variants as a threat to the economic recovery that could alter policy going forward, as well as the generally optimistic tone from Powell in the presser, helped spark a relief rally as the Fed meeting was viewed as being not-as-hawkish-as-feared,” Tom Essaye of the Sevens Report said in a note on Thursday.</p>\n<p>The Fed will begin reducing the pace of its asset purchases in January and buy just $60 billion of bonds each month going forward, compared to $90 billion in the month of December. That decision follows recent inflation data showing a 6.8% surge in November, which is&nbsp;higher than expected and the fastest rate since 1982.</p>\n<p>“The notion that elevated inflation levels would be transitory has finally been thrown out the window by the Fed and the latest policy adjustments are reflective of a committee that doesn’t want to miss the next train leaving the station,” said Charlie Ripley, senior investment strategist for Allianz Investment Management.</p>\n<p>Corporate earnings looked to be a weak spot for the market on Thursday, with shares of Adobe and Lennar falling in premarket trading after underwhelming quarterly reports.</p>\n<p>On the economic data front, weekly jobless claims came in slightly higher than expected, while housing starts for November were much stronger than economists projected after declining in the prior month.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%,Dow climbs 0.5%; S&amp;P 500 advances 0.4%,S&amp;P 500 trades in record-close territory early Thursday.</p>\n<p>Shares of companies that&nbsp;have done well in previous rate-hiking cycles&nbsp;led premarket gainers. Materials stocks FMC Corp. and Freeport-McMoRan both rose more than 3% ahead of the opening bell. Bank stocks also rose across the board, with&nbsp;JPMorgan Chase,Citigroup&nbsp;and&nbsp;Bank of America&nbsp;all up about 0.6%.</p>\n<p>In transportation news,Delta Air Lines&nbsp;reported that it now expects to see a&nbsp;profit of $200 million in the fourth quarter, after previously projecting a loss. Shares rose 2.2% on the news.</p>\n<p>In other central banking news, the Bank of England announced it is hiking its key policy rate by 15 basis points to 0.25%. Markets were awaiting a separate policy decision from the European Central Bank. There also is more economic news on tap, with weekly jobless claims and housing starts out at 8:30 a.m. ET.</p>\n<p>Following the Fed news, traders accelerated their own expectations for interest rate increases. Fed funds futures trading now points to a 63% chance of the first quarter-percentage-point increase coming in May 2022, with chances also rising to about 44% that the central bank could make its first move as soon as March, according to the CME FedWatch Tool.</p>\n<p>Stocks traded in negative territory throughout the regular session Wednesday and turned higher ahead of Fed Chairman Jerome Powell’s press conference in the afternoon at the conclusion of the two-day Federal Open Market Committee meeting. The Dow added 383 points, or 1.08%. The S&amp;P 500 rose 1.63% and the tech-heavy Nasdaq Composite jumped 2.15%.</p>\n<p>“The fact that the FOMC acknowledged new COVID variants as a threat to the economic recovery that could alter policy going forward, as well as the generally optimistic tone from Powell in the presser, helped spark a relief rally as the Fed meeting was viewed as being not-as-hawkish-as-feared,” Tom Essaye of the Sevens Report said in a note on Thursday.</p>\n<p>The Fed will begin reducing the pace of its asset purchases in January and buy just $60 billion of bonds each month going forward, compared to $90 billion in the month of December. That decision follows recent inflation data showing a 6.8% surge in November, which is&nbsp;higher than expected and the fastest rate since 1982.</p>\n<p>“The notion that elevated inflation levels would be transitory has finally been thrown out the window by the Fed and the latest policy adjustments are reflective of a committee that doesn’t want to miss the next train leaving the station,” said Charlie Ripley, senior investment strategist for Allianz Investment Management.</p>\n<p>Corporate earnings looked to be a weak spot for the market on Thursday, with shares of Adobe and Lennar falling in premarket trading after underwhelming quarterly reports.</p>\n<p>On the economic data front, weekly jobless claims came in slightly higher than expected, while housing starts for November were much stronger than economists projected after declining in the prior month.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103611253","content_text":"U.S. stock market opens higher Thursday after Wednesday's Fed-day rally,Nasdaq Composite climbs 0.4%,Dow climbs 0.5%; S&P 500 advances 0.4%,S&P 500 trades in record-close territory early Thursday.\nShares of companies that have done well in previous rate-hiking cycles led premarket gainers. Materials stocks FMC Corp. and Freeport-McMoRan both rose more than 3% ahead of the opening bell. Bank stocks also rose across the board, with JPMorgan Chase,Citigroup and Bank of America all up about 0.6%.\nIn transportation news,Delta Air Lines reported that it now expects to see a profit of $200 million in the fourth quarter, after previously projecting a loss. Shares rose 2.2% on the news.\nIn other central banking news, the Bank of England announced it is hiking its key policy rate by 15 basis points to 0.25%. Markets were awaiting a separate policy decision from the European Central Bank. There also is more economic news on tap, with weekly jobless claims and housing starts out at 8:30 a.m. ET.\nFollowing the Fed news, traders accelerated their own expectations for interest rate increases. Fed funds futures trading now points to a 63% chance of the first quarter-percentage-point increase coming in May 2022, with chances also rising to about 44% that the central bank could make its first move as soon as March, according to the CME FedWatch Tool.\nStocks traded in negative territory throughout the regular session Wednesday and turned higher ahead of Fed Chairman Jerome Powell’s press conference in the afternoon at the conclusion of the two-day Federal Open Market Committee meeting. The Dow added 383 points, or 1.08%. The S&P 500 rose 1.63% and the tech-heavy Nasdaq Composite jumped 2.15%.\n“The fact that the FOMC acknowledged new COVID variants as a threat to the economic recovery that could alter policy going forward, as well as the generally optimistic tone from Powell in the presser, helped spark a relief rally as the Fed meeting was viewed as being not-as-hawkish-as-feared,” Tom Essaye of the Sevens Report said in a note on Thursday.\nThe Fed will begin reducing the pace of its asset purchases in January and buy just $60 billion of bonds each month going forward, compared to $90 billion in the month of December. That decision follows recent inflation data showing a 6.8% surge in November, which is higher than expected and the fastest rate since 1982.\n“The notion that elevated inflation levels would be transitory has finally been thrown out the window by the Fed and the latest policy adjustments are reflective of a committee that doesn’t want to miss the next train leaving the station,” said Charlie Ripley, senior investment strategist for Allianz Investment Management.\nCorporate earnings looked to be a weak spot for the market on Thursday, with shares of Adobe and Lennar falling in premarket trading after underwhelming quarterly reports.\nOn the economic data front, weekly jobless claims came in slightly higher than expected, while housing starts for November were much stronger than economists projected after declining in the prior month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607353417,"gmtCreate":1639492755940,"gmtModify":1639492763552,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607353417","repostId":"2191932169","repostType":2,"isVote":1,"tweetType":1,"viewCount":646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605616949,"gmtCreate":1639151363801,"gmtModify":1639151363866,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Beyond meat","listText":"Beyond meat","text":"Beyond meat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605616949","repostId":"1147480652","repostType":2,"repost":{"id":"1147480652","pubTimestamp":1639125342,"share":"https://www.laohu8.com/m/news/1147480652?lang=&edition=full","pubTime":"2021-12-10 16:35","market":"us","language":"en","title":"3 High-Growth Stocks That Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=1147480652","media":"Motley Fool","summary":"Now is a good time to be greedy and buy up these depressed stocks.","content":"<p>If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.</p>\n<p>Shares of&nbsp;<b>Jazz Pharmaceuticals</b>,<b>DocuSign</b>,and&nbsp;<b>Beyond Meat</b>&nbsp;haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2aaa8c5069132f2d41beafbfbef0705f\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images</span></p>\n<p><b>1. Jazz Pharmaceuticals</b></p>\n<p>Healthcare company&nbsp;Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the&nbsp;<b>S&amp;P 500</b>&nbsp;is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.</p>\n<p>Yet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.</p>\n<p>In fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.</p>\n<p>Prospects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.</p>\n<p><b>2. DocuSign</b></p>\n<p>Anytime a stock&nbsp;falls more than 40% in a&nbsp;<i>single day</i>, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.</p>\n<p>Yet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.</p>\n<p>Unfortunately, in the era of meme stocks, where companies with questionable growth prospects such as&nbsp;<b>AMC Entertainment</b>&nbsp;can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.</p>\n<p>DocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.</p>\n<p>So despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.</p>\n<p><b>3. Beyond Meat</b></p>\n<p>Another stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.</p>\n<p>In 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).</p>\n<p>However, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant&nbsp;<b>McDonald's</b>&nbsp;with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker&nbsp;<b>PepsiCo</b>&nbsp;to develop new products. Beyond Meat also recently launched meatless chicken tenders.</p>\n<p>Things may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 High-Growth Stocks That Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 High-Growth Stocks That Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 16:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","JAZZ":"爵士制药","DOCU":"Docusign"},"source_url":"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147480652","content_text":"If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.\nShares of Jazz Pharmaceuticals,DocuSign,and Beyond Meat haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.\nImage source: Getty Images\n1. Jazz Pharmaceuticals\nHealthcare company Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the S&P 500 is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.\nYet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.\nIn fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.\nProspects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.\n2. DocuSign\nAnytime a stock falls more than 40% in a single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.\nYet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.\nUnfortunately, in the era of meme stocks, where companies with questionable growth prospects such as AMC Entertainment can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.\nDocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.\nSo despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.\n3. Beyond Meat\nAnother stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.\nIn 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).\nHowever, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant McDonald's with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker PepsiCo to develop new products. Beyond Meat also recently launched meatless chicken tenders.\nThings may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.","news_type":1},"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875892565,"gmtCreate":1637630280003,"gmtModify":1637630280003,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875892565","repostId":"1171692239","repostType":2,"repost":{"id":"1171692239","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p>\n<p>Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p>\n<p>Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p>\n<p>The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p>\n<p>Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p>\n<p>\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p>\n<p>An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p>\n<p>Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p>\n<p>Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and ...</p>\n\n<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","SNYNF":"Sanofi","09888":"百度集团-SW"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1},"isVote":1,"tweetType":1,"viewCount":609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876512628,"gmtCreate":1637331273530,"gmtModify":1637331273657,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876512628","repostId":"1144455380","repostType":4,"repost":{"id":"1144455380","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637328728,"share":"https://www.laohu8.com/m/news/1144455380?lang=&edition=full","pubTime":"2021-11-19 21:32","market":"us","language":"en","title":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144455380","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S","content":"<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p>\n<p><img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>\n<p>Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p>\n<p>“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p>\n<p>“Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p>\n<p>In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p>\n<p>A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p>\n<p>Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE stocks climbed about 2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE stocks climbed about 2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p>\n<p><img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>\n<p>Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p>\n<p>“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p>\n<p>“Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p>\n<p>In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p>\n<p>A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p>\n<p>Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144455380","content_text":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.\n\nPfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.\n“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”\n“Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”\nIn October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.\nA booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.\nPfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.","news_type":1},"isVote":1,"tweetType":1,"viewCount":663,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871904658,"gmtCreate":1637016989498,"gmtModify":1637016989498,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[OMG]&nbsp;","listText":"[OMG]&nbsp;","text":"[OMG]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871904658","repostId":"1172705595","repostType":4,"repost":{"id":"1172705595","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636967300,"share":"https://www.laohu8.com/m/news/1172705595?lang=&edition=full","pubTime":"2021-11-15 17:08","market":"us","language":"en","title":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1172705595","media":"Tiger Newspress","summary":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks.According to the SEC doc","content":"<p>Tesla slid over 2% in premarket trading as&nbsp;Musk&nbsp;sold&nbsp;$6.9 billion in stocks.<img src=\"https://static.tigerbbs.com/5a221e68493f92069795f4cb1ba56aa5\" tg-width=\"765\" tg-height=\"566\" width=\"100%\" height=\"auto\">According to the SEC documents,Tesla&nbsp;CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.</p>\n<p>According to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.</p>\n<p>Just before selling Tesla Motors shares, on November 6, Musk was in&nbsp;Twitter&nbsp;To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-15 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla slid over 2% in premarket trading as&nbsp;Musk&nbsp;sold&nbsp;$6.9 billion in stocks.<img src=\"https://static.tigerbbs.com/5a221e68493f92069795f4cb1ba56aa5\" tg-width=\"765\" tg-height=\"566\" width=\"100%\" height=\"auto\">According to the SEC documents,Tesla&nbsp;CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.</p>\n<p>According to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.</p>\n<p>Just before selling Tesla Motors shares, on November 6, Musk was in&nbsp;Twitter&nbsp;To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172705595","content_text":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks.According to the SEC documents,Tesla CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.\nAccording to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.\nJust before selling Tesla Motors shares, on November 6, Musk was in Twitter To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.","news_type":1},"isVote":1,"tweetType":1,"viewCount":872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857874840,"gmtCreate":1635519984474,"gmtModify":1635519984474,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/857874840","repostId":"2179105882","repostType":4,"repost":{"id":"2179105882","pubTimestamp":1635511238,"share":"https://www.laohu8.com/m/news/2179105882?lang=&edition=full","pubTime":"2021-10-29 20:40","market":"us","language":"en","title":"2 Unstoppable Stocks That Could Turn $50,000 Into $250,000 by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2179105882","media":"Motley Fool","summary":"The stock market sell-off during September and October appears to have subsided, with the S&P 500 in","content":"<p>The stock market sell-off during September and October appears to have subsided, with the <b>S&amp;P 500</b> index now back to its all-time highs. The dip was just 5% at its worst, so some investors might be feeling that it wasn't much of a buying opportunity.</p>\n<p>But it's important to stay focused on the long term, and remember that time in the market is more important than timing the market. Investors who buy stocks today probably won't be dwelling on their entry prices when the year 2030 rolls around.</p>\n<p>Here are two innovative technology stocks that could grow fivefold by then, and they can be bought right now.</p>\n<h2>1. The case for DocuSign</h2>\n<p><b>DocuSign </b>(NASDAQ:DOCU) is best known as the leader in digital signature technology. It was having plenty of success prior to the pandemic, but when work-from-home trends kicked in, the company's growth rate exploded. This new dynamic appears to be sticking around, and DocuSign's expanding product portfolio stands to yield long-term rewards.</p>\n<p>The company is investing in emerging technologies like artificial intelligence to deliver the next generation of digital-document innovation. The DocuSign Insight platform can read and analyze legal contracts to identify problematic clauses or potential opportunities, saving companies time and money.</p>\n<p>It's especially helpful for organizations that issue and receive a high volume of contracts because the cost of retaining a team of lawyers can be astronomical. While Insight isn't ready to replace these professionals just yet, artificial intelligence promises a future that almost makes it inevitable.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metric</p></th>\n   <th><p>Fiscal 2019</p></th>\n   <th><p>Fiscal 2022 (Estimate)</p></th>\n   <th><p>CAGR</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td><p>Revenue</p></td>\n   <td><p>$701.0 million</p></td>\n   <td><p>$2.1 billion</p></td>\n   <td><p>43.8%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: DocuSign. CAGR = compound annual growth rate.</p>\n<p>Assuming DocuSign's price-to-sales ratio remains the same, it would need to grow revenue by about 20% per year for its stock to rise fivefold by 2030. Right now, its revenue is growing at <i>double </i>that pace. But perhaps more significantly, the company is expected to reverse its history of losses by generating $1.75 in earnings per share in the current fiscal year, which ends Jan. 31, 2022.</p>\n<p>Among the Wall Street analysts that cover DocuSign, none of them recommend selling the stock. With a strong vote of confidence from the professionals, a future grounded in innovative technology, and the numbers to back it up, DocuSign looks like a great bet to turn $50,000 into $250,000 by 2030.</p>\n<h2>2. The case for Redfin</h2>\n<p>Unlike DocuSign, <b>Redfin</b> (NASDAQ:RDFN) isn't trying to reinvent the wheel. It operates in the real estate sales industry, and it's taking existing processes and simply trying to make them better (and cheaper) -- and it's having enormous success.</p>\n<p>Most real estate agents are either independent or work within a small firm that's dedicated to a specific city or geographic area. They charge listing fees of around 2.5%, which are costly for the seller, but selling a house is a huge financial decision that most people aren't willing to attempt without professional help.</p>\n<p>Redfin is disrupting the traditional model by employing thousands of agents who operate in every major jurisdiction across the U.S. By building such scale, the company is able to charge listing fees of just 1%, and it has already saved consumers over $1 billion since its inception. The proposition is a win for Redfin and home-sellers alike, driving soaring revenue growth as a result.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metric</p></th>\n   <th><p>2018</p></th>\n   <th><p>2021 (Estimate)</p></th>\n   <th><p>CAGR</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td><p>Revenue</p></td>\n   <td><p>$486.9 million</p></td>\n   <td><p>$1.8 billion</p></td>\n   <td><p>54%</p></td>\n  </tr>\n  <tr>\n   <td><p>Redfin Share of U.S. Home Sales</p></td>\n   <td><p>0.81%</p></td>\n   <td><p>1.18% (Current)</p></td>\n   <td><p>N/A</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data sources: Redfin, Yahoo! Finance.</p>\n<p>Redfin's market share of total homes sold continues to climb, further highlighting the company's popularity among consumers. But the company isn't a one-dimensional sales agency; it also has a small presence in the technology-driven iBuying business, where it purchases homes directly from sellers and flips them for a profit.</p>\n<p>The company sold 463 homes using this method in the first half of 2021, representing 39% growth compared to the first half of 2020. While strong, almost all of Redfin's gross profit still comes from selling homes the traditional way.</p>\n<p>Like DocuSign, Redfin is crushing the 20% revenue growth rate it needs to potentially rise fivefold by 2030. It operates in a $36 trillion industry and as it continues to snatch market share, it's an exciting opportunity for investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Unstoppable Stocks That Could Turn $50,000 Into $250,000 by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Unstoppable Stocks That Could Turn $50,000 Into $250,000 by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-29 20:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/29/2-unstoppable-stocks-turn-50000-to-250000-by-2030/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market sell-off during September and October appears to have subsided, with the S&P 500 index now back to its all-time highs. The dip was just 5% at its worst, so some investors might be ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/29/2-unstoppable-stocks-turn-50000-to-250000-by-2030/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RDFN":"Redfin Corp","DOCU":"Docusign"},"source_url":"https://www.fool.com/investing/2021/10/29/2-unstoppable-stocks-turn-50000-to-250000-by-2030/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179105882","content_text":"The stock market sell-off during September and October appears to have subsided, with the S&P 500 index now back to its all-time highs. The dip was just 5% at its worst, so some investors might be feeling that it wasn't much of a buying opportunity.\nBut it's important to stay focused on the long term, and remember that time in the market is more important than timing the market. Investors who buy stocks today probably won't be dwelling on their entry prices when the year 2030 rolls around.\nHere are two innovative technology stocks that could grow fivefold by then, and they can be bought right now.\n1. The case for DocuSign\nDocuSign (NASDAQ:DOCU) is best known as the leader in digital signature technology. It was having plenty of success prior to the pandemic, but when work-from-home trends kicked in, the company's growth rate exploded. This new dynamic appears to be sticking around, and DocuSign's expanding product portfolio stands to yield long-term rewards.\nThe company is investing in emerging technologies like artificial intelligence to deliver the next generation of digital-document innovation. The DocuSign Insight platform can read and analyze legal contracts to identify problematic clauses or potential opportunities, saving companies time and money.\nIt's especially helpful for organizations that issue and receive a high volume of contracts because the cost of retaining a team of lawyers can be astronomical. While Insight isn't ready to replace these professionals just yet, artificial intelligence promises a future that almost makes it inevitable.\n\n\n\nMetric\nFiscal 2019\nFiscal 2022 (Estimate)\nCAGR\n\n\n\n\nRevenue\n$701.0 million\n$2.1 billion\n43.8%\n\n\n\nData source: DocuSign. CAGR = compound annual growth rate.\nAssuming DocuSign's price-to-sales ratio remains the same, it would need to grow revenue by about 20% per year for its stock to rise fivefold by 2030. Right now, its revenue is growing at double that pace. But perhaps more significantly, the company is expected to reverse its history of losses by generating $1.75 in earnings per share in the current fiscal year, which ends Jan. 31, 2022.\nAmong the Wall Street analysts that cover DocuSign, none of them recommend selling the stock. With a strong vote of confidence from the professionals, a future grounded in innovative technology, and the numbers to back it up, DocuSign looks like a great bet to turn $50,000 into $250,000 by 2030.\n2. The case for Redfin\nUnlike DocuSign, Redfin (NASDAQ:RDFN) isn't trying to reinvent the wheel. It operates in the real estate sales industry, and it's taking existing processes and simply trying to make them better (and cheaper) -- and it's having enormous success.\nMost real estate agents are either independent or work within a small firm that's dedicated to a specific city or geographic area. They charge listing fees of around 2.5%, which are costly for the seller, but selling a house is a huge financial decision that most people aren't willing to attempt without professional help.\nRedfin is disrupting the traditional model by employing thousands of agents who operate in every major jurisdiction across the U.S. By building such scale, the company is able to charge listing fees of just 1%, and it has already saved consumers over $1 billion since its inception. The proposition is a win for Redfin and home-sellers alike, driving soaring revenue growth as a result.\n\n\n\nMetric\n2018\n2021 (Estimate)\nCAGR\n\n\n\n\nRevenue\n$486.9 million\n$1.8 billion\n54%\n\n\nRedfin Share of U.S. Home Sales\n0.81%\n1.18% (Current)\nN/A\n\n\n\nData sources: Redfin, Yahoo! Finance.\nRedfin's market share of total homes sold continues to climb, further highlighting the company's popularity among consumers. But the company isn't a one-dimensional sales agency; it also has a small presence in the technology-driven iBuying business, where it purchases homes directly from sellers and flips them for a profit.\nThe company sold 463 homes using this method in the first half of 2021, representing 39% growth compared to the first half of 2020. While strong, almost all of Redfin's gross profit still comes from selling homes the traditional way.\nLike DocuSign, Redfin is crushing the 20% revenue growth rate it needs to potentially rise fivefold by 2030. It operates in a $36 trillion industry and as it continues to snatch market share, it's an exciting opportunity for investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826454412,"gmtCreate":1634049065098,"gmtModify":1634049255820,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826454412","repostId":"1155597565","repostType":4,"repost":{"id":"1155597565","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634045433,"share":"https://www.laohu8.com/m/news/1155597565?lang=&edition=full","pubTime":"2021-10-12 21:30","market":"us","language":"zh","title":"开盘：美股齐涨，中概教育股迎利好普涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1155597565","media":"老虎资讯综合","summary":"道琼斯指数开盘上涨81.78点，涨幅0.24%，报34577.84点。","content":"<p>10月12日（周二），美股集体高开。道琼斯指数开盘上涨81.78点，涨幅0.24%，报34577.84点；标普500指数开盘上涨9.74点，涨幅0.22%，报4370.93点；纳斯达克综合指数开盘上涨47.4点，涨幅0.33%，报14533.6点。</p>\n<p><img src=\"https://static.tigerbbs.com/a183018f38f6dbae57ddf2d97d445410\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>中概教育股盘初走高，<a href=\"https://laohu8.com/S/GOTU\">高途</a>涨超8%，<a href=\"https://laohu8.com/S/TAL\">好未来</a>涨4.83%，<a href=\"https://laohu8.com/S/EDU\">新东方</a>涨1.56%。消息面上，<b>中国发布《关于推动现代职业教育高质量发展的意见》。意见表示，鼓励上市公司、行业龙头企业举办职业教育，鼓励各类企业依法参与举办职业教育。鼓励职业学校与社会资本合作共建职业教育基础设施、实训基地，共建共享公共实训基地。</b></p>\n<p><a href=\"https://laohu8.com/S/ONE\">精锐教育</a>停牌。IR网站发布消息称，公司董事会批准暂停所有在中国的教育项目和学习中心。公司同时宣布，其独立董事徐梁（Mason）和龚彦于近日辞去董事会职务。</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>开盘涨约1.7%，9月<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>国产车批发销量创造出56,006辆的全新纪录，同比增长394%。</p>\n<p>美股新能源车板块多数走高，<a href=\"https://laohu8.com/S/TSP\">图森未来</a>涨近4%，<a href=\"https://laohu8.com/S/LCID\">Lucid Group</a>涨3%，<a href=\"https://laohu8.com/S/WKHS\">Workhorse</a>涨2.81%，<a href=\"https://laohu8.com/S/F\">福特</a>涨1.69%。</p>\n<p><a href=\"https://laohu8.com/S/GSK\">葛兰素史克</a>涨超2%，消息面上，公司消费者业务据悉吸引收购兴趣，估值或超400亿英镑，据悉公司同时筹备将该业务上市。</p>\n<p><a href=\"https://laohu8.com/S/OCGN\">Ocugen</a>涨超9%，印度专家委员建议授予Ocugen合作伙伴Bharat Biotech的新冠疫苗2至18岁儿童紧急使用授权。</p>\n<p>生物制药公司<a href=\"https://laohu8.com/S/CVAC\">Curevac</a>跌超10%，公司第一批新冠疫苗将退出欧洲药品管理局(EMA)监管审查。</p>\n<p><a href=\"https://laohu8.com/S/NKE\">耐克</a>涨1.83%，此前高盛首予耐克172美元的目标价和买入评级。</p>\n<p><a href=\"https://laohu8.com/S/ABNB\">爱彼迎</a>涨5.22%，此前获华尔街资管公司科文上调评级至跑赢大市。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>开盘：美股齐涨，中概教育股迎利好普涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n开盘：美股齐涨，中概教育股迎利好普涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-10-12 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>10月12日（周二），美股集体高开。道琼斯指数开盘上涨81.78点，涨幅0.24%，报34577.84点；标普500指数开盘上涨9.74点，涨幅0.22%，报4370.93点；纳斯达克综合指数开盘上涨47.4点，涨幅0.33%，报14533.6点。</p>\n<p><img src=\"https://static.tigerbbs.com/a183018f38f6dbae57ddf2d97d445410\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>中概教育股盘初走高，<a href=\"https://laohu8.com/S/GOTU\">高途</a>涨超8%，<a href=\"https://laohu8.com/S/TAL\">好未来</a>涨4.83%，<a href=\"https://laohu8.com/S/EDU\">新东方</a>涨1.56%。消息面上，<b>中国发布《关于推动现代职业教育高质量发展的意见》。意见表示，鼓励上市公司、行业龙头企业举办职业教育，鼓励各类企业依法参与举办职业教育。鼓励职业学校与社会资本合作共建职业教育基础设施、实训基地，共建共享公共实训基地。</b></p>\n<p><a href=\"https://laohu8.com/S/ONE\">精锐教育</a>停牌。IR网站发布消息称，公司董事会批准暂停所有在中国的教育项目和学习中心。公司同时宣布，其独立董事徐梁（Mason）和龚彦于近日辞去董事会职务。</p>\n<p><a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>开盘涨约1.7%，9月<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>国产车批发销量创造出56,006辆的全新纪录，同比增长394%。</p>\n<p>美股新能源车板块多数走高，<a href=\"https://laohu8.com/S/TSP\">图森未来</a>涨近4%，<a href=\"https://laohu8.com/S/LCID\">Lucid Group</a>涨3%，<a href=\"https://laohu8.com/S/WKHS\">Workhorse</a>涨2.81%，<a href=\"https://laohu8.com/S/F\">福特</a>涨1.69%。</p>\n<p><a href=\"https://laohu8.com/S/GSK\">葛兰素史克</a>涨超2%，消息面上，公司消费者业务据悉吸引收购兴趣，估值或超400亿英镑，据悉公司同时筹备将该业务上市。</p>\n<p><a href=\"https://laohu8.com/S/OCGN\">Ocugen</a>涨超9%，印度专家委员建议授予Ocugen合作伙伴Bharat Biotech的新冠疫苗2至18岁儿童紧急使用授权。</p>\n<p>生物制药公司<a href=\"https://laohu8.com/S/CVAC\">Curevac</a>跌超10%，公司第一批新冠疫苗将退出欧洲药品管理局(EMA)监管审查。</p>\n<p><a href=\"https://laohu8.com/S/NKE\">耐克</a>涨1.83%，此前高盛首予耐克172美元的目标价和买入评级。</p>\n<p><a href=\"https://laohu8.com/S/ABNB\">爱彼迎</a>涨5.22%，此前获华尔街资管公司科文上调评级至跑赢大市。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","relate_stocks":{".DJI":"道琼斯"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155597565","content_text":"10月12日（周二），美股集体高开。道琼斯指数开盘上涨81.78点，涨幅0.24%，报34577.84点；标普500指数开盘上涨9.74点，涨幅0.22%，报4370.93点；纳斯达克综合指数开盘上涨47.4点，涨幅0.33%，报14533.6点。\n\n中概教育股盘初走高，高途涨超8%，好未来涨4.83%，新东方涨1.56%。消息面上，中国发布《关于推动现代职业教育高质量发展的意见》。意见表示，鼓励上市公司、行业龙头企业举办职业教育，鼓励各类企业依法参与举办职业教育。鼓励职业学校与社会资本合作共建职业教育基础设施、实训基地，共建共享公共实训基地。\n精锐教育停牌。IR网站发布消息称，公司董事会批准暂停所有在中国的教育项目和学习中心。公司同时宣布，其独立董事徐梁（Mason）和龚彦于近日辞去董事会职务。\n特斯拉开盘涨约1.7%，9月特斯拉国产车批发销量创造出56,006辆的全新纪录，同比增长394%。\n美股新能源车板块多数走高，图森未来涨近4%，Lucid Group涨3%，Workhorse涨2.81%，福特涨1.69%。\n葛兰素史克涨超2%，消息面上，公司消费者业务据悉吸引收购兴趣，估值或超400亿英镑，据悉公司同时筹备将该业务上市。\nOcugen涨超9%，印度专家委员建议授予Ocugen合作伙伴Bharat Biotech的新冠疫苗2至18岁儿童紧急使用授权。\n生物制药公司Curevac跌超10%，公司第一批新冠疫苗将退出欧洲药品管理局(EMA)监管审查。\n耐克涨1.83%，此前高盛首予耐克172美元的目标价和买入评级。\n爱彼迎涨5.22%，此前获华尔街资管公司科文上调评级至跑赢大市。","news_type":1},"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821996180,"gmtCreate":1633682669489,"gmtModify":1633682669580,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821996180","repostId":"1118881509","repostType":4,"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823893455,"gmtCreate":1633609422585,"gmtModify":1633609422669,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/823893455","repostId":"1100842347","repostType":4,"repost":{"id":"1100842347","pubTimestamp":1633608853,"share":"https://www.laohu8.com/m/news/1100842347?lang=&edition=full","pubTime":"2021-10-07 20:14","market":"us","language":"en","title":"Nio gains after Goldman Sachs points to 60% upside potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1100842347","media":"seekingalpha","summary":"$NIO Inc.$  jumps in early trading after $Goldman Sachs$ moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.The positive vibe from Goldman is based off Nio's  positioning with the ET7 model in the same class as the Mercedes S-class and BMW 7 series. Looking toward the end of the year, the Nio Day event in December is seen as a potential share price catalyst.Goldman Sachs assigns a price target of $56 to rep more than 60% upside. Shares of Nio  areup 4.87%in p","content":"<p><b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a> </b>&nbsp;jumps in early trading after <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.</p>\n<p><img src=\"https://static.tigerbbs.com/336eaf8c6b70c9f830659cff60abe973\" tg-width=\"1062\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p>\n<p>The positive vibe from Goldman is based off Nio's (NIO)&nbsp;positioning with the ET7 model in the same class as the Mercedes S-class and BMW 7 series. Looking toward the end of the year, the Nio Day event in December is seen as a potential share price catalyst.</p>\n<p>Goldman Sachs assigns a price target of $56 to rep more than 60% upside. Shares of Nio (NIO) areup 4.87%in premarket action to $35.30.</p>\n<p>Nio landed on&nbsp;Wedbush's Dream <a href=\"https://laohu8.com/S/TISI\">Team</a> of EV stocks yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/4b7eb8eed0f5ab2653909aa55660de3d\" tg-width=\"340\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio gains after Goldman Sachs points to 60% upside potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio gains after Goldman Sachs points to 60% upside potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-07 20:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750551-nio-gains-after-goldman-sachs-points-to-60-upside-potential><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NIO Inc.  jumps in early trading after Goldman Sachs moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.\n\nThe positive vibe from Goldman is based off Nio's (NIO) ...</p>\n\n<a href=\"https://seekingalpha.com/news/3750551-nio-gains-after-goldman-sachs-points-to-60-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/news/3750551-nio-gains-after-goldman-sachs-points-to-60-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1100842347","content_text":"NIO Inc.  jumps in early trading after Goldman Sachs moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.\n\nThe positive vibe from Goldman is based off Nio's (NIO) positioning with the ET7 model in the same class as the Mercedes S-class and BMW 7 series. Looking toward the end of the year, the Nio Day event in December is seen as a potential share price catalyst.\nGoldman Sachs assigns a price target of $56 to rep more than 60% upside. Shares of Nio (NIO) areup 4.87%in premarket action to $35.30.\nNio landed on Wedbush's Dream Team of EV stocks yesterday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865489470,"gmtCreate":1633010852109,"gmtModify":1633010852245,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865489470","repostId":"1190243332","repostType":4,"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862169738,"gmtCreate":1632844016820,"gmtModify":1632844016820,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862169738","repostId":"1126986798","repostType":4,"repost":{"id":"1126986798","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632827257,"share":"https://www.laohu8.com/m/news/1126986798?lang=&edition=full","pubTime":"2021-09-28 19:07","market":"us","language":"en","title":"Sonoma Pharmaceuticals shares surged 45% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126986798","media":"Tiger Newspress","summary":"Sonoma Pharmaceuticals shares surged 45% in premarket trading after launching its first over-the-cou","content":"<p>Sonoma Pharmaceuticals shares surged 45% in premarket trading&nbsp;after&nbsp;launching its first over-the-counter products in the U.S. on amazon and a new consumer-focused product on amazon in Europe.</p>\n<p><img src=\"https://static.tigerbbs.com/1b36dd566a7aa3d834858c9e28652591\" tg-width=\"850\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter (“OTC”) consumer launch of Regenacyn®Advanced Scar Gel and Ocucyn®Eyelid &amp; Eyelash Cleanser on Amazon.com, and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn®technology and are immediately available for customer orders.</p>\n<p>Sonoma&nbsp;offers its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn®technology widely available for all.</p>\n<p>Regenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.</p>\n<p>Ocucyn Eyelid &amp; Eyelash Cleanser, designed for everyday use, is a safe, gentle &amp; effective solution for good eyelid &amp; eyelash hygiene. Ocucyn Eyelid &amp; Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid &amp; Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.</p>\n<p>MucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.</p>\n<p><b>About Sonoma Pharmaceuticals, Inc.</b></p>\n<p>Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonoma Pharmaceuticals shares surged 45% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonoma Pharmaceuticals shares surged 45% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-28 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sonoma Pharmaceuticals shares surged 45% in premarket trading&nbsp;after&nbsp;launching its first over-the-counter products in the U.S. on amazon and a new consumer-focused product on amazon in Europe.</p>\n<p><img src=\"https://static.tigerbbs.com/1b36dd566a7aa3d834858c9e28652591\" tg-width=\"850\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter (“OTC”) consumer launch of Regenacyn®Advanced Scar Gel and Ocucyn®Eyelid &amp; Eyelash Cleanser on Amazon.com, and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn®technology and are immediately available for customer orders.</p>\n<p>Sonoma&nbsp;offers its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn®technology widely available for all.</p>\n<p>Regenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.</p>\n<p>Ocucyn Eyelid &amp; Eyelash Cleanser, designed for everyday use, is a safe, gentle &amp; effective solution for good eyelid &amp; eyelash hygiene. Ocucyn Eyelid &amp; Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid &amp; Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.</p>\n<p>MucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.</p>\n<p><b>About Sonoma Pharmaceuticals, Inc.</b></p>\n<p>Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNOA":"Sonoma Pharmaceuticals, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126986798","content_text":"Sonoma Pharmaceuticals shares surged 45% in premarket trading after launching its first over-the-counter products in the U.S. on amazon and a new consumer-focused product on amazon in Europe.\n\nSonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter (“OTC”) consumer launch of Regenacyn®Advanced Scar Gel and Ocucyn®Eyelid & Eyelash Cleanser on Amazon.com, and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn®technology and are immediately available for customer orders.\nSonoma offers its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn®technology widely available for all.\nRegenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.\nOcucyn Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle & effective solution for good eyelid & eyelash hygiene. Ocucyn Eyelid & Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid & Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.\nMucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.\nAbout Sonoma Pharmaceuticals, Inc.\nSonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.","news_type":1},"isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866016206,"gmtCreate":1632711422205,"gmtModify":1632798373666,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866016206","repostId":"1118093911","repostType":2,"repost":{"id":"1118093911","pubTimestamp":1632379417,"share":"https://www.laohu8.com/m/news/1118093911?lang=&edition=full","pubTime":"2021-09-23 14:43","market":"us","language":"en","title":"China's Xiaomi invests $2B in auto-chip company Black Sesame","url":"https://stock-news.laohu8.com/highlight/detail?id=1118093911","media":"seekingalpha","summary":"Chinese automotive semiconductor company Black Sesame said Wednesday it has reached a valuation of a","content":"<p>Chinese automotive semiconductor company Black Sesame said Wednesday it has reached a valuation of almost $2 billion after receiving an investment from Beijing-based Xiaomi(OTCPK:XIACF).</p>\n<p>Black Sesame didn't give an exact amount of the Xiaomi (OTCPK:XIACF) investment, but said it was worth \"hundreds of millions of dollars.\"</p>\n<p>Xiaomi (OTCPK:XIACF) is one of China's largest consumer electronics companies, and operates across its home country, as well as India and parts of Europe. The investment comes amid an ongoing shortage of semiconductor components that has had a particular impact on the automotive industry.</p>\n<p>Among leading chip companies, Intel(NASDAQ:INTC), Advanced Micro Devices(NASDAQ:AMD), NVIDIA(NASDAQ:NVDA), Applied Materials(NASDAQ:AMAT)and KLA(NASDAQ:KLAC)all saw their shares rise in pre-market trading Wednesday.</p>\n<p>Earlier this week, Honda(NYSE:HMC)said its factories in Japan were running at 40% capacity due to the chip shortage,and that production should be at 70% capacity in October.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Xiaomi invests $2B in auto-chip company Black Sesame</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Xiaomi invests $2B in auto-chip company Black Sesame\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 14:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3742246-chinas-xiaomi-invests-2b-in-auto-chip-company-black-sesame><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese automotive semiconductor company Black Sesame said Wednesday it has reached a valuation of almost $2 billion after receiving an investment from Beijing-based Xiaomi(OTCPK:XIACF).\nBlack Sesame ...</p>\n\n<a href=\"https://seekingalpha.com/news/3742246-chinas-xiaomi-invests-2b-in-auto-chip-company-black-sesame\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01810":"小米集团-W","XIACY":"小米集团ADR"},"source_url":"https://seekingalpha.com/news/3742246-chinas-xiaomi-invests-2b-in-auto-chip-company-black-sesame","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1118093911","content_text":"Chinese automotive semiconductor company Black Sesame said Wednesday it has reached a valuation of almost $2 billion after receiving an investment from Beijing-based Xiaomi(OTCPK:XIACF).\nBlack Sesame didn't give an exact amount of the Xiaomi (OTCPK:XIACF) investment, but said it was worth \"hundreds of millions of dollars.\"\nXiaomi (OTCPK:XIACF) is one of China's largest consumer electronics companies, and operates across its home country, as well as India and parts of Europe. The investment comes amid an ongoing shortage of semiconductor components that has had a particular impact on the automotive industry.\nAmong leading chip companies, Intel(NASDAQ:INTC), Advanced Micro Devices(NASDAQ:AMD), NVIDIA(NASDAQ:NVDA), Applied Materials(NASDAQ:AMAT)and KLA(NASDAQ:KLAC)all saw their shares rise in pre-market trading Wednesday.\nEarlier this week, Honda(NYSE:HMC)said its factories in Japan were running at 40% capacity due to the chip shortage,and that production should be at 70% capacity in October.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":808488365,"gmtCreate":1627606135457,"gmtModify":1633757876899,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"好的开始是成功的一半","listText":"好的开始是成功的一半","text":"好的开始是成功的一半","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808488365","repostId":"2155197992","repostType":2,"isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":690648910,"gmtCreate":1639666223435,"gmtModify":1639666223552,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690648910","repostId":"1103611253","repostType":4,"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857874840,"gmtCreate":1635519984474,"gmtModify":1635519984474,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/857874840","repostId":"2179105882","repostType":4,"isVote":1,"tweetType":1,"viewCount":578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696318694,"gmtCreate":1640617094472,"gmtModify":1640617232336,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696318694","repostId":"1139095230","repostType":4,"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607353417,"gmtCreate":1639492755940,"gmtModify":1639492763552,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607353417","repostId":"2191932169","repostType":2,"repost":{"id":"2191932169","pubTimestamp":1639483069,"share":"https://www.laohu8.com/m/news/2191932169?lang=&edition=full","pubTime":"2021-12-14 19:57","market":"us","language":"en","title":"4 Growth Stocks With 119% to 189% Upside in 2022, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2191932169","media":"Motley Fool","summary":"Select analysts and investment banks see these fast-paced stocks soaring next year.","content":"<p>In less than three weeks, Wall Street is likely going to uncork the champagne on what's been another successful year for the broader market. Through this past weekend, the benchmark <b>S&amp;P 500</b> was higher by 25% for the year, which is more than double the average annual total return of the widely followed index since the beginning of 1980.</p>\n<p>But according to some analysts, there are still some big gains to be had. Based on the high-water one-year price targets issued by analysts and investment banks, the following four growth stocks are expected to deliver upside of 119% to as much as 189% in 2022.</p>\n<h2>Nio: Implied upside of 154%</h2>\n<p>First up is electric vehicle (EV) manufacturer <b>Nio</b> (NYSE:NIO). EV stocks have been particularly hot for over a year now, with Nio offering some of the strongest expected upside. Based on the highest currency-converted price target among financial institutions, Nio is expected to reach almost $87 in 2022. This gives it an implied upside of a cool 154%.</p>\n<p>Earlier this year, it looked as if the company wouldn't have any issues ramping up production to an annual run-rate of 150,000 EVs. However, this plan was tossed out the window during the second and third quarters due to supply chain concerns and a semiconductor chip shortage. With the latter beginning to resolve, Nio delivered a record 10,878 vehicles in November.</p>\n<p>For those of you keeping score at home, this works out to an annualized run-rate of 130,536 EVs.&nbsp; By this time next year, Nio could be producing closer to 600,000 vehicles on an annual run-rate basis.</p>\n<p>And it's not just Nio's production ramp-up that has Wall Street excited. Innovation will play a key role in its success. The company has already introduced three EV models, with plans to launch three new vehicles in 2022.</p>\n<p>To build on the above, it also introduced the battery-as-a-service (BaaS) solution in 2020. The BaaS model reduces the upfront cost of new EVs in exchange for enrollment in a monthly fee-based service. This service allows owners to replace or upgrade their batteries in the future. In giving up some near-term revenue, Nio has secured juicier long-term cash flow and found a way to keep buyers loyal to the brand.</p>\n<p>Plus, it doesn't hurt that Nio is based in China, the No. 1 auto market in the world. While an $87 price target might be asking a bit much, momentum is definitely in Nio's favor in 2022.</p>\n<h2>Redfin: Implied upside of 119%</h2>\n<p>Another high-growth stock that's the apple of at least one Wall Street firm's eye is technology-driven real estate platform <b>Redfin</b> (NASDAQ:RDFN). With an $88 price target, Truist Securities is expecting up to 119% upside in Redfin's shares over the coming year.</p>\n<p>The Redfin growth thesis is built on two drivers. First, it's undercutting the competition on a cost basis. Whereas traditional real estate firms charge their clients a 2.5% or 3% listing fee/commission, Redfin charges its clients either 1% or 1.5%, depending on how much previous business has been done with the company. In October, the average selling price of a new home in the U.S. was $477,800.&nbsp; With a peak difference of up to two percentage points in listing fees/commission, Redfin can save its clients around $9,500!</p>\n<p>On top of big savings, Redfin brings personalization to the table in what's otherwise a stodgy industry ripe for disruption. It offers a Concierge service to help clients maximize the selling value of their home, as well as an iBuyer program that purchases homes from sellers with cash. The company benefited from offering 3D and virtual home tours during the pandemic, too.</p>\n<p>The big question for Redfin is how it's going to fare with interest rates, and therefore mortgage rates, expected to climb a bit in 2022 and 2023. While homebuying activity does tend to abate during periods of higher lending rates, Redfin's core advantages could keep its proverbial hamster on the wheel while other real estate companies falter.</p>\n<p>As with Nio, expecting this peak price target to hit in 2022 is far too optimistic. But Redfin does offer a bright future for patient shareholders.</p>\n<h2>Vaxart: Implied upside of 189%</h2>\n<p>For a supercharged upside opportunity in 2022, at least one analyst believes you should buy clinical-stage biotech stock <b>Vaxart</b> (NASDAQ:VXRT). Analyst Yasmeen Rahimi of Piper Sandler expects Vaxart to hit $18 in 2022, which implies a gain of 189% from where it closed this past weekend.</p>\n<p>Like Redfin, there are two factors that make Vaxart tick. To begin with, the company's future is reliant on its VAAST platform. This stands for \"Vector-Adjuvant-Antigen Standardized Technology.\" Without getting too technical, Vaxart aims to differentiate itself by developing drug candidates in oral formulation that are typically administered as a vaccine. This makes administration easier and safer (no chance of an accidental needle prick), and it targets both systemic and mucosal immunity.</p>\n<p>The other catalyst putting Vaxart on the map is its experimental oral coronavirus disease 2019 (COVID-19) treatment. While you might have seen news of oral COVID-19 pills targeted at already-infected patients, Vaxart's oral tablet is designed to act as a vaccine for healthy individuals.</p>\n<p>The $64,000 question is: Will it work? Although an early stage study demonstrated an immune response, high levels of neutralizing antibodies, which have been observed following traditional COVID-19 vaccines, weren't present. Vaxart is specifically targeting the S-protein in its mid-stage trial and expecting better results.</p>\n<p>Unless Vaxart's results rival the efficacy seen with traditional vaccines, it could be difficult for the company to reach a lofty $18 price target in 2022.</p>\n<h2><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications: Implied upside of 143%</h2>\n<p>Last, but not least, cloud-based video conferencing platform <b>Zoom Video Communications</b> (NASDAQ:ZM) is expected to offer significant upside in 2022. With a Wall Street high-water price target of $450, the recently battered Zoom could offer gains of 143% in the upcoming year.</p>\n<p>Zoom was a huge winner during the pandemic. With the traditional office environment disrupted, remote work and virtual meetings became commonplace -- so much so that \"Zoom\" became its own verb.</p>\n<p>What needs to be questioned now is whether Zoom can keep growing with the low-hanging fruit of the pandemic now in the rearview mirror. For the moment, the answer does look to be that it'll sustain double-digit growth potential. Zoom brings efficiencies to the table for businesses of all sizes that should prove valuable in a hybrid or traditional work environment.</p>\n<p>It's been a particularly popular solution among smaller businesses. Although we think of Zoom as winning over major clients during the pandemic, the company's bread-and-butter has been wooing small and medium-sized businesses. According to Zoom, it's had 14 consecutive quarters of a net dollar expansion rate of at least 130% for businesses with 10 or more employees. In English, this means existing customers with 10 or more employees have spent at least 30% more from the previous year for 3.5 years (and counting!).</p>\n<p>There's no doubt Zoom will need to remain innovative and look at acquisition opportunities to command a premium valuation. While a price target of $450 in 2022 sounds too aggressive, it is a target that can eventually be reached by shares in the future.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Growth Stocks With 119% to 189% Upside in 2022, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Growth Stocks With 119% to 189% Upside in 2022, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/14/4-growth-stocks-119-to-189-upside-2022-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In less than three weeks, Wall Street is likely going to uncork the champagne on what's been another successful year for the broader market. Through this past weekend, the benchmark S&P 500 was higher...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/14/4-growth-stocks-119-to-189-upside-2022-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","RDFN":"Redfin Corp","BK4079":"房地产服务","BK4505":"高瓴资本持仓","BK4504":"桥水持仓","BK4099":"汽车制造商","NIO":"蔚来","BK4548":"巴美列捷福持仓","BK4528":"SaaS概念","BK4023":"应用软件","VXRT":"Vaxart, Inc","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","ZM":"Zoom","BK4531":"中概回港概念","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4555":"新能源车","BK4509":"腾讯概念","BK4525":"远程办公概念","BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","BK4526":"热门中概股"},"source_url":"https://www.fool.com/investing/2021/12/14/4-growth-stocks-119-to-189-upside-2022-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191932169","content_text":"In less than three weeks, Wall Street is likely going to uncork the champagne on what's been another successful year for the broader market. Through this past weekend, the benchmark S&P 500 was higher by 25% for the year, which is more than double the average annual total return of the widely followed index since the beginning of 1980.\nBut according to some analysts, there are still some big gains to be had. Based on the high-water one-year price targets issued by analysts and investment banks, the following four growth stocks are expected to deliver upside of 119% to as much as 189% in 2022.\nNio: Implied upside of 154%\nFirst up is electric vehicle (EV) manufacturer Nio (NYSE:NIO). EV stocks have been particularly hot for over a year now, with Nio offering some of the strongest expected upside. Based on the highest currency-converted price target among financial institutions, Nio is expected to reach almost $87 in 2022. This gives it an implied upside of a cool 154%.\nEarlier this year, it looked as if the company wouldn't have any issues ramping up production to an annual run-rate of 150,000 EVs. However, this plan was tossed out the window during the second and third quarters due to supply chain concerns and a semiconductor chip shortage. With the latter beginning to resolve, Nio delivered a record 10,878 vehicles in November.\nFor those of you keeping score at home, this works out to an annualized run-rate of 130,536 EVs.  By this time next year, Nio could be producing closer to 600,000 vehicles on an annual run-rate basis.\nAnd it's not just Nio's production ramp-up that has Wall Street excited. Innovation will play a key role in its success. The company has already introduced three EV models, with plans to launch three new vehicles in 2022.\nTo build on the above, it also introduced the battery-as-a-service (BaaS) solution in 2020. The BaaS model reduces the upfront cost of new EVs in exchange for enrollment in a monthly fee-based service. This service allows owners to replace or upgrade their batteries in the future. In giving up some near-term revenue, Nio has secured juicier long-term cash flow and found a way to keep buyers loyal to the brand.\nPlus, it doesn't hurt that Nio is based in China, the No. 1 auto market in the world. While an $87 price target might be asking a bit much, momentum is definitely in Nio's favor in 2022.\nRedfin: Implied upside of 119%\nAnother high-growth stock that's the apple of at least one Wall Street firm's eye is technology-driven real estate platform Redfin (NASDAQ:RDFN). With an $88 price target, Truist Securities is expecting up to 119% upside in Redfin's shares over the coming year.\nThe Redfin growth thesis is built on two drivers. First, it's undercutting the competition on a cost basis. Whereas traditional real estate firms charge their clients a 2.5% or 3% listing fee/commission, Redfin charges its clients either 1% or 1.5%, depending on how much previous business has been done with the company. In October, the average selling price of a new home in the U.S. was $477,800.  With a peak difference of up to two percentage points in listing fees/commission, Redfin can save its clients around $9,500!\nOn top of big savings, Redfin brings personalization to the table in what's otherwise a stodgy industry ripe for disruption. It offers a Concierge service to help clients maximize the selling value of their home, as well as an iBuyer program that purchases homes from sellers with cash. The company benefited from offering 3D and virtual home tours during the pandemic, too.\nThe big question for Redfin is how it's going to fare with interest rates, and therefore mortgage rates, expected to climb a bit in 2022 and 2023. While homebuying activity does tend to abate during periods of higher lending rates, Redfin's core advantages could keep its proverbial hamster on the wheel while other real estate companies falter.\nAs with Nio, expecting this peak price target to hit in 2022 is far too optimistic. But Redfin does offer a bright future for patient shareholders.\nVaxart: Implied upside of 189%\nFor a supercharged upside opportunity in 2022, at least one analyst believes you should buy clinical-stage biotech stock Vaxart (NASDAQ:VXRT). Analyst Yasmeen Rahimi of Piper Sandler expects Vaxart to hit $18 in 2022, which implies a gain of 189% from where it closed this past weekend.\nLike Redfin, there are two factors that make Vaxart tick. To begin with, the company's future is reliant on its VAAST platform. This stands for \"Vector-Adjuvant-Antigen Standardized Technology.\" Without getting too technical, Vaxart aims to differentiate itself by developing drug candidates in oral formulation that are typically administered as a vaccine. This makes administration easier and safer (no chance of an accidental needle prick), and it targets both systemic and mucosal immunity.\nThe other catalyst putting Vaxart on the map is its experimental oral coronavirus disease 2019 (COVID-19) treatment. While you might have seen news of oral COVID-19 pills targeted at already-infected patients, Vaxart's oral tablet is designed to act as a vaccine for healthy individuals.\nThe $64,000 question is: Will it work? Although an early stage study demonstrated an immune response, high levels of neutralizing antibodies, which have been observed following traditional COVID-19 vaccines, weren't present. Vaxart is specifically targeting the S-protein in its mid-stage trial and expecting better results.\nUnless Vaxart's results rival the efficacy seen with traditional vaccines, it could be difficult for the company to reach a lofty $18 price target in 2022.\nZoom Video Communications: Implied upside of 143%\nLast, but not least, cloud-based video conferencing platform Zoom Video Communications (NASDAQ:ZM) is expected to offer significant upside in 2022. With a Wall Street high-water price target of $450, the recently battered Zoom could offer gains of 143% in the upcoming year.\nZoom was a huge winner during the pandemic. With the traditional office environment disrupted, remote work and virtual meetings became commonplace -- so much so that \"Zoom\" became its own verb.\nWhat needs to be questioned now is whether Zoom can keep growing with the low-hanging fruit of the pandemic now in the rearview mirror. For the moment, the answer does look to be that it'll sustain double-digit growth potential. Zoom brings efficiencies to the table for businesses of all sizes that should prove valuable in a hybrid or traditional work environment.\nIt's been a particularly popular solution among smaller businesses. Although we think of Zoom as winning over major clients during the pandemic, the company's bread-and-butter has been wooing small and medium-sized businesses. According to Zoom, it's had 14 consecutive quarters of a net dollar expansion rate of at least 130% for businesses with 10 or more employees. In English, this means existing customers with 10 or more employees have spent at least 30% more from the previous year for 3.5 years (and counting!).\nThere's no doubt Zoom will need to remain innovative and look at acquisition opportunities to command a premium valuation. While a price target of $450 in 2022 sounds too aggressive, it is a target that can eventually be reached by shares in the future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699118924,"gmtCreate":1639755143620,"gmtModify":1639755143863,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699118924","repostId":"2192462941","repostType":2,"isVote":1,"tweetType":1,"viewCount":1304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823893455,"gmtCreate":1633609422585,"gmtModify":1633609422669,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/823893455","repostId":"1100842347","repostType":4,"repost":{"id":"1100842347","pubTimestamp":1633608853,"share":"https://www.laohu8.com/m/news/1100842347?lang=&edition=full","pubTime":"2021-10-07 20:14","market":"us","language":"en","title":"Nio gains after Goldman Sachs points to 60% upside potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1100842347","media":"seekingalpha","summary":"$NIO Inc.$  jumps in early trading after $Goldman Sachs$ moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.The positive vibe from Goldman is based off Nio's  positioning with the ET7 model in the same class as the Mercedes S-class and BMW 7 series. Looking toward the end of the year, the Nio Day event in December is seen as a potential share price catalyst.Goldman Sachs assigns a price target of $56 to rep more than 60% upside. Shares of Nio  areup 4.87%in p","content":"<p><b><a href=\"https://laohu8.com/S/NIO\">NIO Inc.</a> </b>&nbsp;jumps in early trading after <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.</p>\n<p><img src=\"https://static.tigerbbs.com/336eaf8c6b70c9f830659cff60abe973\" tg-width=\"1062\" tg-height=\"571\" referrerpolicy=\"no-referrer\"></p>\n<p>The positive vibe from Goldman is based off Nio's (NIO)&nbsp;positioning with the ET7 model in the same class as the Mercedes S-class and BMW 7 series. Looking toward the end of the year, the Nio Day event in December is seen as a potential share price catalyst.</p>\n<p>Goldman Sachs assigns a price target of $56 to rep more than 60% upside. Shares of Nio (NIO) areup 4.87%in premarket action to $35.30.</p>\n<p>Nio landed on&nbsp;Wedbush's Dream <a href=\"https://laohu8.com/S/TISI\">Team</a> of EV stocks yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/4b7eb8eed0f5ab2653909aa55660de3d\" tg-width=\"340\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio gains after Goldman Sachs points to 60% upside potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio gains after Goldman Sachs points to 60% upside potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-07 20:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750551-nio-gains-after-goldman-sachs-points-to-60-upside-potential><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NIO Inc.  jumps in early trading after Goldman Sachs moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.\n\nThe positive vibe from Goldman is based off Nio's (NIO) ...</p>\n\n<a href=\"https://seekingalpha.com/news/3750551-nio-gains-after-goldman-sachs-points-to-60-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/news/3750551-nio-gains-after-goldman-sachs-points-to-60-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1100842347","content_text":"NIO Inc.  jumps in early trading after Goldman Sachs moves to a Buy rating on the electric vehicle maker after having a Neutral stance on it.\n\nThe positive vibe from Goldman is based off Nio's (NIO) positioning with the ET7 model in the same class as the Mercedes S-class and BMW 7 series. Looking toward the end of the year, the Nio Day event in December is seen as a potential share price catalyst.\nGoldman Sachs assigns a price target of $56 to rep more than 60% upside. Shares of Nio (NIO) areup 4.87%in premarket action to $35.30.\nNio landed on Wedbush's Dream Team of EV stocks yesterday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698075573,"gmtCreate":1640270565309,"gmtModify":1640270565416,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698075573","repostId":"1140408431","repostType":4,"isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876512628,"gmtCreate":1637331273530,"gmtModify":1637331273657,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876512628","repostId":"1144455380","repostType":4,"isVote":1,"tweetType":1,"viewCount":663,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826454412,"gmtCreate":1634049065098,"gmtModify":1634049255820,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826454412","repostId":"1155597565","repostType":4,"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821996180,"gmtCreate":1633682669489,"gmtModify":1633682669580,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821996180","repostId":"1118881509","repostType":4,"repost":{"id":"1118881509","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633680221,"share":"https://www.laohu8.com/m/news/1118881509?lang=&edition=full","pubTime":"2021-10-08 16:03","market":"us","language":"en","title":"Sundial Growers gained nearly 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118881509","media":"Tiger Newspress","summary":"(Oct 8) Sundial Growers Inc. gained nearly 17% in premarket trading, the company buys Alcanna in C$3","content":"<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/SNDL\">Sundial Growers Inc.</a></b> gained nearly 17% in premarket trading,&nbsp;the&nbsp;company buys Alcanna in C$346M all-stock deal.</p>\n<p><img src=\"https://static.tigerbbs.com/bbc0301b5f501f1d7d3629926b2f568b\" tg-width=\"1064\" tg-height=\"576\" referrerpolicy=\"no-referrer\">Alcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.</p>\n<p>\"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.</p>\n<p>Seeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sundial Growers gained nearly 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSundial Growers gained nearly 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-08 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Oct 8)&nbsp;<b><a href=\"https://laohu8.com/S/SNDL\">Sundial Growers Inc.</a></b> gained nearly 17% in premarket trading,&nbsp;the&nbsp;company buys Alcanna in C$346M all-stock deal.</p>\n<p><img src=\"https://static.tigerbbs.com/bbc0301b5f501f1d7d3629926b2f568b\" tg-width=\"1064\" tg-height=\"576\" referrerpolicy=\"no-referrer\">Alcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.</p>\n<p>\"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.</p>\n<p>Seeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNDL":"SNDL Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118881509","content_text":"(Oct 8) Sundial Growers Inc. gained nearly 17% in premarket trading, the company buys Alcanna in C$346M all-stock deal.\nAlcanna is Canada's largest private liquor retailer, operating 171 locations mostly in Alberta, but its majority-owned subsidiary is Canadian cannabis retailer Nova Cannabis.\n\"Alcanna's value-focused model in liquor retailing has created market stability and we believe that the replication of this playbook in cannabis has strong potential to drive a similar result,\" Sundial CEO Zach George says.\nSeeking Alpha contributor IncomeBent Investments sees Sundial Growers asa speculative buy as the Canadian cannabis industry works out the long-term sector leaders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865489470,"gmtCreate":1633010852109,"gmtModify":1633010852245,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865489470","repostId":"1190243332","repostType":4,"repost":{"id":"1190243332","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633008705,"share":"https://www.laohu8.com/m/news/1190243332?lang=&edition=full","pubTime":"2021-09-30 21:31","market":"us","language":"en","title":"Stocks rise slightly as Wall Street tries to end losing month on a high note","url":"https://stock-news.laohu8.com/highlight/detail?id=1190243332","media":"Tiger Newspress","summary":"U.S. stocks rose slightly on Thursday as investors get to close out a volatile and losing month for ","content":"<p>U.S. stocks rose slightly on Thursday as investors get to close out a volatile and losing month for stocks.</p>\n<p>The Dow Jones Industrial Average gained 107 points, or 0.3%. The S&amp;P 500 added 0.4% and Nasdaq Composite gained 0.6%.</p>\n<p>Tech stocks bounced a bit in morning trading after struggling this week because of a rapid rise in rates. The&nbsp;10-year Treasury yield&nbsp;was little changed in early trading.</p>\n<p>Chip stocks, including Nvidia and Micron, were higher after weighing on the broader market on Wednesday. Facebook and Apple saw modest gains in early trading, while Netflix jumped more than 2%.</p>\n<p>Stocks also got a boost as Senate Majority Leader Chuck Schumer said late Wednesday that the chamber had reached a deal to avoid a government shutdown this week. Schumer said&nbsp;he would schedule a vote on Thursday&nbsp;for the stopgap measure that would keep the government running into early December. The deal would still need to pass the House.</p>\n<p>For the month, the Dow is down 2.7%, the S&amp;P 500 is off by 3.6% and the Nasdaq Composite has shed 4.9%. September has lived up to its losing reputation with the market beset by fears of a China property crisis, rising inflation and a late interest rate surge sparked by the Federal Reserve signaling it would start removing stimulus soon.</p>\n<p>\"We wouldn't get caught up in any end-of-quarter machinations today and continue to advise fading rallies (especially in tech) as the coming weeks will stay rocky,\" wrote Adam Crisafulli of Vital Knowledge.</p>\n<p>The 10-year Treasury yield fell 3 basis points to 1.52% on Thursday (1 basis point equals 0.01%). The rate was at 1.30% to end August before surging to end this month.</p>\n<p>September’s losses have led to a middling third quarter for the market. For the 3-month period, the Dow is slightly in the red, while the Nasdaq Composite is just about flat. The S&amp;P 500 is up 1.4%. The S&amp;P 500 is still up 16% on the year.</p>\n<p>October has a reputation for some violent sell-offs but overall is typically the start of a better seasonal performance for stocks. The S&amp;P 500 averages a 0.8% gain for the month, according to the Stock Trader’s Almanac.</p>\n<p>“September lived up to its reputation and dented stock portfolio returns, but not too badly,” wrote Ed Yardeni of Yardeni Research. “There has been a lot of concern that higher wages, higher energy prices, and higher transportation costs will weigh on earnings for the remainder of this year and into 2022. It’s certainly something we’ll be tracking. But so far, analysts remain relatively sanguine.”</p>\n<p>Concerns about inflation and supply chain issues continued to hamper stocks.Shares of Bed Bath &amp; Beyond fell more than 28%&nbsp;in morning&nbsp; trading after the company said those issues hurt the company’s second quarter results, and the news also weighed on fellow retail stocks.</p>\n<p>Fed Chair Jerome Powell will testify to the House Financial Services Committee at 10 a.m. ET Thursday alongside Treasury Secretary Janet Yellen. Powell&nbsp;told a European Central Bank panel on Wednesday&nbsp;that he was frustrated by persistent inflation.</p>\n<p>“It’s also frustrating to see the bottlenecks and supply chain problems not getting better — in fact at the margins apparently getting a little bit worse,” Powell said. “We see that continuing into next year probably, and holding up inflation longer than we had thought.”</p>\n<p>On the data front,initial jobless claims&nbsp;for the prior week came in at 362,000. Economists are expecting a print of 335,000, according to Dow Jones.</p>\n<p>The Dow and S&amp;P 500 inched higher during regular trading Wednesday. The 30-stock Dow advanced about 90 points for its fifth positive session in the last six, while the S&amp;P 500 gained 0.16%, breaking a 2-day losing streak.</p>\n<p>The Nasdaq Composite, meanwhile, declined 0.24% for its fourth straight negative session. The technology sector declined again on Wednesday and is now down 4% for the week, making it the worst-performing S&amp;P group.</p>\n<p>The tech decline came as the 10-year Treasury yield hit a high of 1.56% on Wednesday, after rising to 1.567% on Tuesday. The move higher is pressuring tech stocks since it makes future cash flows look less attractive.</p>\n<p>Wells Fargo noted that pullbacks are to be expected. \"This is a normal re-pricing of risk based on a higher cost of capital and greater market uncertainty,\" the firm said Wednesday in a note to clients.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks rise slightly as Wall Street tries to end losing month on a high note</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks rise slightly as Wall Street tries to end losing month on a high note\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-30 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stocks rose slightly on Thursday as investors get to close out a volatile and losing month for stocks.</p>\n<p>The Dow Jones Industrial Average gained 107 points, or 0.3%. The S&amp;P 500 added 0.4% and Nasdaq Composite gained 0.6%.</p>\n<p>Tech stocks bounced a bit in morning trading after struggling this week because of a rapid rise in rates. The&nbsp;10-year Treasury yield&nbsp;was little changed in early trading.</p>\n<p>Chip stocks, including Nvidia and Micron, were higher after weighing on the broader market on Wednesday. Facebook and Apple saw modest gains in early trading, while Netflix jumped more than 2%.</p>\n<p>Stocks also got a boost as Senate Majority Leader Chuck Schumer said late Wednesday that the chamber had reached a deal to avoid a government shutdown this week. Schumer said&nbsp;he would schedule a vote on Thursday&nbsp;for the stopgap measure that would keep the government running into early December. The deal would still need to pass the House.</p>\n<p>For the month, the Dow is down 2.7%, the S&amp;P 500 is off by 3.6% and the Nasdaq Composite has shed 4.9%. September has lived up to its losing reputation with the market beset by fears of a China property crisis, rising inflation and a late interest rate surge sparked by the Federal Reserve signaling it would start removing stimulus soon.</p>\n<p>\"We wouldn't get caught up in any end-of-quarter machinations today and continue to advise fading rallies (especially in tech) as the coming weeks will stay rocky,\" wrote Adam Crisafulli of Vital Knowledge.</p>\n<p>The 10-year Treasury yield fell 3 basis points to 1.52% on Thursday (1 basis point equals 0.01%). The rate was at 1.30% to end August before surging to end this month.</p>\n<p>September’s losses have led to a middling third quarter for the market. For the 3-month period, the Dow is slightly in the red, while the Nasdaq Composite is just about flat. The S&amp;P 500 is up 1.4%. The S&amp;P 500 is still up 16% on the year.</p>\n<p>October has a reputation for some violent sell-offs but overall is typically the start of a better seasonal performance for stocks. The S&amp;P 500 averages a 0.8% gain for the month, according to the Stock Trader’s Almanac.</p>\n<p>“September lived up to its reputation and dented stock portfolio returns, but not too badly,” wrote Ed Yardeni of Yardeni Research. “There has been a lot of concern that higher wages, higher energy prices, and higher transportation costs will weigh on earnings for the remainder of this year and into 2022. It’s certainly something we’ll be tracking. But so far, analysts remain relatively sanguine.”</p>\n<p>Concerns about inflation and supply chain issues continued to hamper stocks.Shares of Bed Bath &amp; Beyond fell more than 28%&nbsp;in morning&nbsp; trading after the company said those issues hurt the company’s second quarter results, and the news also weighed on fellow retail stocks.</p>\n<p>Fed Chair Jerome Powell will testify to the House Financial Services Committee at 10 a.m. ET Thursday alongside Treasury Secretary Janet Yellen. Powell&nbsp;told a European Central Bank panel on Wednesday&nbsp;that he was frustrated by persistent inflation.</p>\n<p>“It’s also frustrating to see the bottlenecks and supply chain problems not getting better — in fact at the margins apparently getting a little bit worse,” Powell said. “We see that continuing into next year probably, and holding up inflation longer than we had thought.”</p>\n<p>On the data front,initial jobless claims&nbsp;for the prior week came in at 362,000. Economists are expecting a print of 335,000, according to Dow Jones.</p>\n<p>The Dow and S&amp;P 500 inched higher during regular trading Wednesday. The 30-stock Dow advanced about 90 points for its fifth positive session in the last six, while the S&amp;P 500 gained 0.16%, breaking a 2-day losing streak.</p>\n<p>The Nasdaq Composite, meanwhile, declined 0.24% for its fourth straight negative session. The technology sector declined again on Wednesday and is now down 4% for the week, making it the worst-performing S&amp;P group.</p>\n<p>The tech decline came as the 10-year Treasury yield hit a high of 1.56% on Wednesday, after rising to 1.567% on Tuesday. The move higher is pressuring tech stocks since it makes future cash flows look less attractive.</p>\n<p>Wells Fargo noted that pullbacks are to be expected. \"This is a normal re-pricing of risk based on a higher cost of capital and greater market uncertainty,\" the firm said Wednesday in a note to clients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190243332","content_text":"U.S. stocks rose slightly on Thursday as investors get to close out a volatile and losing month for stocks.\nThe Dow Jones Industrial Average gained 107 points, or 0.3%. The S&P 500 added 0.4% and Nasdaq Composite gained 0.6%.\nTech stocks bounced a bit in morning trading after struggling this week because of a rapid rise in rates. The 10-year Treasury yield was little changed in early trading.\nChip stocks, including Nvidia and Micron, were higher after weighing on the broader market on Wednesday. Facebook and Apple saw modest gains in early trading, while Netflix jumped more than 2%.\nStocks also got a boost as Senate Majority Leader Chuck Schumer said late Wednesday that the chamber had reached a deal to avoid a government shutdown this week. Schumer said he would schedule a vote on Thursday for the stopgap measure that would keep the government running into early December. The deal would still need to pass the House.\nFor the month, the Dow is down 2.7%, the S&P 500 is off by 3.6% and the Nasdaq Composite has shed 4.9%. September has lived up to its losing reputation with the market beset by fears of a China property crisis, rising inflation and a late interest rate surge sparked by the Federal Reserve signaling it would start removing stimulus soon.\n\"We wouldn't get caught up in any end-of-quarter machinations today and continue to advise fading rallies (especially in tech) as the coming weeks will stay rocky,\" wrote Adam Crisafulli of Vital Knowledge.\nThe 10-year Treasury yield fell 3 basis points to 1.52% on Thursday (1 basis point equals 0.01%). The rate was at 1.30% to end August before surging to end this month.\nSeptember’s losses have led to a middling third quarter for the market. For the 3-month period, the Dow is slightly in the red, while the Nasdaq Composite is just about flat. The S&P 500 is up 1.4%. The S&P 500 is still up 16% on the year.\nOctober has a reputation for some violent sell-offs but overall is typically the start of a better seasonal performance for stocks. The S&P 500 averages a 0.8% gain for the month, according to the Stock Trader’s Almanac.\n“September lived up to its reputation and dented stock portfolio returns, but not too badly,” wrote Ed Yardeni of Yardeni Research. “There has been a lot of concern that higher wages, higher energy prices, and higher transportation costs will weigh on earnings for the remainder of this year and into 2022. It’s certainly something we’ll be tracking. But so far, analysts remain relatively sanguine.”\nConcerns about inflation and supply chain issues continued to hamper stocks.Shares of Bed Bath & Beyond fell more than 28% in morning  trading after the company said those issues hurt the company’s second quarter results, and the news also weighed on fellow retail stocks.\nFed Chair Jerome Powell will testify to the House Financial Services Committee at 10 a.m. ET Thursday alongside Treasury Secretary Janet Yellen. Powell told a European Central Bank panel on Wednesday that he was frustrated by persistent inflation.\n“It’s also frustrating to see the bottlenecks and supply chain problems not getting better — in fact at the margins apparently getting a little bit worse,” Powell said. “We see that continuing into next year probably, and holding up inflation longer than we had thought.”\nOn the data front,initial jobless claims for the prior week came in at 362,000. Economists are expecting a print of 335,000, according to Dow Jones.\nThe Dow and S&P 500 inched higher during regular trading Wednesday. The 30-stock Dow advanced about 90 points for its fifth positive session in the last six, while the S&P 500 gained 0.16%, breaking a 2-day losing streak.\nThe Nasdaq Composite, meanwhile, declined 0.24% for its fourth straight negative session. The technology sector declined again on Wednesday and is now down 4% for the week, making it the worst-performing S&P group.\nThe tech decline came as the 10-year Treasury yield hit a high of 1.56% on Wednesday, after rising to 1.567% on Tuesday. The move higher is pressuring tech stocks since it makes future cash flows look less attractive.\nWells Fargo noted that pullbacks are to be expected. \"This is a normal re-pricing of risk based on a higher cost of capital and greater market uncertainty,\" the firm said Wednesday in a note to clients.","news_type":1},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862169738,"gmtCreate":1632844016820,"gmtModify":1632844016820,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862169738","repostId":"1126986798","repostType":4,"repost":{"id":"1126986798","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632827257,"share":"https://www.laohu8.com/m/news/1126986798?lang=&edition=full","pubTime":"2021-09-28 19:07","market":"us","language":"en","title":"Sonoma Pharmaceuticals shares surged 45% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126986798","media":"Tiger Newspress","summary":"Sonoma Pharmaceuticals shares surged 45% in premarket trading after launching its first over-the-cou","content":"<p>Sonoma Pharmaceuticals shares surged 45% in premarket trading&nbsp;after&nbsp;launching its first over-the-counter products in the U.S. on amazon and a new consumer-focused product on amazon in Europe.</p>\n<p><img src=\"https://static.tigerbbs.com/1b36dd566a7aa3d834858c9e28652591\" tg-width=\"850\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter (“OTC”) consumer launch of Regenacyn®Advanced Scar Gel and Ocucyn®Eyelid &amp; Eyelash Cleanser on Amazon.com, and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn®technology and are immediately available for customer orders.</p>\n<p>Sonoma&nbsp;offers its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn®technology widely available for all.</p>\n<p>Regenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.</p>\n<p>Ocucyn Eyelid &amp; Eyelash Cleanser, designed for everyday use, is a safe, gentle &amp; effective solution for good eyelid &amp; eyelash hygiene. Ocucyn Eyelid &amp; Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid &amp; Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.</p>\n<p>MucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.</p>\n<p><b>About Sonoma Pharmaceuticals, Inc.</b></p>\n<p>Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonoma Pharmaceuticals shares surged 45% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonoma Pharmaceuticals shares surged 45% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-28 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sonoma Pharmaceuticals shares surged 45% in premarket trading&nbsp;after&nbsp;launching its first over-the-counter products in the U.S. on amazon and a new consumer-focused product on amazon in Europe.</p>\n<p><img src=\"https://static.tigerbbs.com/1b36dd566a7aa3d834858c9e28652591\" tg-width=\"850\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter (“OTC”) consumer launch of Regenacyn®Advanced Scar Gel and Ocucyn®Eyelid &amp; Eyelash Cleanser on Amazon.com, and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn®technology and are immediately available for customer orders.</p>\n<p>Sonoma&nbsp;offers its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn®technology widely available for all.</p>\n<p>Regenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.</p>\n<p>Ocucyn Eyelid &amp; Eyelash Cleanser, designed for everyday use, is a safe, gentle &amp; effective solution for good eyelid &amp; eyelash hygiene. Ocucyn Eyelid &amp; Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid &amp; Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.</p>\n<p>MucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.</p>\n<p><b>About Sonoma Pharmaceuticals, Inc.</b></p>\n<p>Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNOA":"Sonoma Pharmaceuticals, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126986798","content_text":"Sonoma Pharmaceuticals shares surged 45% in premarket trading after launching its first over-the-counter products in the U.S. on amazon and a new consumer-focused product on amazon in Europe.\n\nSonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter (“OTC”) consumer launch of Regenacyn®Advanced Scar Gel and Ocucyn®Eyelid & Eyelash Cleanser on Amazon.com, and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn®technology and are immediately available for customer orders.\nSonoma offers its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn®technology widely available for all.\nRegenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.\nOcucyn Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle & effective solution for good eyelid & eyelash hygiene. Ocucyn Eyelid & Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid & Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.\nMucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.\nAbout Sonoma Pharmaceuticals, Inc.\nSonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.","news_type":1},"isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605616949,"gmtCreate":1639151363801,"gmtModify":1639151363866,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Beyond meat","listText":"Beyond meat","text":"Beyond meat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605616949","repostId":"1147480652","repostType":2,"repost":{"id":"1147480652","pubTimestamp":1639125342,"share":"https://www.laohu8.com/m/news/1147480652?lang=&edition=full","pubTime":"2021-12-10 16:35","market":"us","language":"en","title":"3 High-Growth Stocks That Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=1147480652","media":"Motley Fool","summary":"Now is a good time to be greedy and buy up these depressed stocks.","content":"<p>If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.</p>\n<p>Shares of&nbsp;<b>Jazz Pharmaceuticals</b>,<b>DocuSign</b>,and&nbsp;<b>Beyond Meat</b>&nbsp;haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2aaa8c5069132f2d41beafbfbef0705f\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images</span></p>\n<p><b>1. Jazz Pharmaceuticals</b></p>\n<p>Healthcare company&nbsp;Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the&nbsp;<b>S&amp;P 500</b>&nbsp;is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.</p>\n<p>Yet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.</p>\n<p>In fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.</p>\n<p>Prospects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.</p>\n<p><b>2. DocuSign</b></p>\n<p>Anytime a stock&nbsp;falls more than 40% in a&nbsp;<i>single day</i>, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.</p>\n<p>Yet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.</p>\n<p>Unfortunately, in the era of meme stocks, where companies with questionable growth prospects such as&nbsp;<b>AMC Entertainment</b>&nbsp;can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.</p>\n<p>DocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.</p>\n<p>So despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.</p>\n<p><b>3. Beyond Meat</b></p>\n<p>Another stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.</p>\n<p>In 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).</p>\n<p>However, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant&nbsp;<b>McDonald's</b>&nbsp;with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker&nbsp;<b>PepsiCo</b>&nbsp;to develop new products. Beyond Meat also recently launched meatless chicken tenders.</p>\n<p>Things may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 High-Growth Stocks That Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 High-Growth Stocks That Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 16:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","JAZZ":"爵士制药","DOCU":"Docusign"},"source_url":"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147480652","content_text":"If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.\nShares of Jazz Pharmaceuticals,DocuSign,and Beyond Meat haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.\nImage source: Getty Images\n1. Jazz Pharmaceuticals\nHealthcare company Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the S&P 500 is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.\nYet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.\nIn fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.\nProspects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.\n2. DocuSign\nAnytime a stock falls more than 40% in a single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.\nYet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.\nUnfortunately, in the era of meme stocks, where companies with questionable growth prospects such as AMC Entertainment can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.\nDocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.\nSo despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.\n3. Beyond Meat\nAnother stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.\nIn 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).\nHowever, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant McDonald's with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker PepsiCo to develop new products. Beyond Meat also recently launched meatless chicken tenders.\nThings may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.","news_type":1},"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875892565,"gmtCreate":1637630280003,"gmtModify":1637630280003,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875892565","repostId":"1171692239","repostType":2,"repost":{"id":"1171692239","pubTimestamp":1637582731,"share":"https://www.laohu8.com/m/news/1171692239?lang=&edition=full","pubTime":"2021-11-22 20:05","market":"us","language":"en","title":"Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development","url":"https://stock-news.laohu8.com/highlight/detail?id=1171692239","media":"Reuters","summary":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its ","content":"<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.</p>\n<p>Sanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more</p>\n<p>Sanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.</p>\n<p>The French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.</p>\n<p>Baidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.</p>\n<p>\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.</p>\n<p>An mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.</p>\n<p>Baidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.</p>\n<p>Specifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to&nbsp;lab studies and animal tests, which haven't gone through peer-review.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaidu in partnership with Sanofi to use its algorithm in mRNA vaccine, therapy development\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and ...</p>\n\n<a href=\"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIDU":"百度","SNYNF":"Sanofi","09888":"百度集团-SW"},"source_url":"https://www.reuters.com/markets/europe/baidu-partnership-with-sanofi-use-its-algorithm-mrna-vaccine-therapy-development-2021-11-22/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171692239","content_text":"BEIJING, Nov 22 (Reuters) - Chinese tech giant Baidu Inc(9888.HK)said on Monday it has licensed its algorithm for messenger RNA (mRNA) sequence to Sanofi SA for use in designing vaccine and therapeutic products, entering its first such commercial deal with a major global drugmaker.\nSanofi(SASY.PA)had been one of the world's biggest vaccine makers before the pandemic, but the French firm was beaten by rivals BioNTech /Pfizer(PFE.N)and Moderna(MRNA.O)in developing mRNA shots against COVID-19.read more\nSanofi stopped trials of its own mRNA COVID-19 shot in September, and is instead focusing on efforts with GlaxoSmithKline(GSK.L)to bring another COVID-19 vaccine candidate to market based on the more conventional protein-based approach.\nThe French groupsaidit would focus its mRNA resources on other infectious diseases and therapeutics with strong unmet need.\nBaidu will receive milestone payments when any mRNA-based therapy or vaccine candidate discovered by Sanofi using its algorithm enters clinical trials, said Huang Liang, a Baidu scientist leading the project.\n\"The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with Baidu algorithm into clinical trials and to the market,\" Huang told Reuters. He declined to disclose the size of the deal.\nAn mRNA-based vaccine contains mRNA sequence which instructs human cells to produce proteins that can spur the immune system into action.\nBaidu's algorithm is designed to deliver a larger number of optimised mRNA sequences and there are early signs that it could be more suitable than standard algorithms in vaccine and therapeutic drug development, Huang said.\nSpecifically regarding COVID-19 vaccine candidates, those containing mRNA sequences generated by Baidu's algorithm were more stable and appeared to require a smaller dosage than a baseline shot based on a standard algorithm, according to lab studies and animal tests, which haven't gone through peer-review.","news_type":1},"isVote":1,"tweetType":1,"viewCount":609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871904658,"gmtCreate":1637016989498,"gmtModify":1637016989498,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[OMG]&nbsp;","listText":"[OMG]&nbsp;","text":"[OMG]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871904658","repostId":"1172705595","repostType":4,"repost":{"id":"1172705595","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636967300,"share":"https://www.laohu8.com/m/news/1172705595?lang=&edition=full","pubTime":"2021-11-15 17:08","market":"us","language":"en","title":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1172705595","media":"Tiger Newspress","summary":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks.According to the SEC doc","content":"<p>Tesla slid over 2% in premarket trading as&nbsp;Musk&nbsp;sold&nbsp;$6.9 billion in stocks.<img src=\"https://static.tigerbbs.com/5a221e68493f92069795f4cb1ba56aa5\" tg-width=\"765\" tg-height=\"566\" width=\"100%\" height=\"auto\">According to the SEC documents,Tesla&nbsp;CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.</p>\n<p>According to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.</p>\n<p>Just before selling Tesla Motors shares, on November 6, Musk was in&nbsp;Twitter&nbsp;To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-15 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla slid over 2% in premarket trading as&nbsp;Musk&nbsp;sold&nbsp;$6.9 billion in stocks.<img src=\"https://static.tigerbbs.com/5a221e68493f92069795f4cb1ba56aa5\" tg-width=\"765\" tg-height=\"566\" width=\"100%\" height=\"auto\">According to the SEC documents,Tesla&nbsp;CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.</p>\n<p>According to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.</p>\n<p>Just before selling Tesla Motors shares, on November 6, Musk was in&nbsp;Twitter&nbsp;To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172705595","content_text":"Tesla slid over 2% in premarket trading as Musk sold $6.9 billion in stocks.According to the SEC documents,Tesla CEO Musk sold 1.2 million Tesla Motors shares held by his trust fund on November 12, worth more than $1.2 billion.\nAccording to media statistics, up to now, Musk has sold about 6.36 million Tesla Motors shares in the week since November 8, with a total value of nearly 6.9 billion US dollars (equivalent to about 44 billion yuan), and Tesla Motors's share price has also dropped by more than 15% in three days.\nJust before selling Tesla Motors shares, on November 6, Musk was in Twitter To ask 62.7 million fans whether they should sell 10% of Tesla Motors shares (worth $21 billion). He also said that regardless of the outcome, he would \"abide by the voting results\". The final vote showed that about 58% of the participants supported the sale.","news_type":1},"isVote":1,"tweetType":1,"viewCount":872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866016206,"gmtCreate":1632711422205,"gmtModify":1632798373666,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866016206","repostId":"1118093911","repostType":2,"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":808488365,"gmtCreate":1627606135457,"gmtModify":1633757876899,"author":{"id":"3573647345754035","authorId":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"好的开始是成功的一半","listText":"好的开始是成功的一半","text":"好的开始是成功的一半","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808488365","repostId":"2155197992","repostType":2,"isVote":1,"tweetType":1,"viewCount":168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}